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ABSTRACT 
BONNIE LISA BARR, Synthesis and Evaluation of Cocaine Analogs for Activity as 
Cocaine Antagonists and Synthesis of Novel Prodrugs with Antiarthritic Potential. 
(Under the guidance of JAMES E. WYNN, Ph. D.) 
As a follow up to interest in a new class of agents that have potential for the treatment 
of arthritic conditions, two series of cocaine derivatives were synthesized. Specifically, 
an N-alkyl series consisting of the ethyl, n-propyl, isopropyl, n-butyl and benzyl 
norcocaine derivatives and an N-acyl series consisting of the acetyl, propionyl, butyryl, 
and benzoyl norcocaine derivatives were synthesized. The structures of these 
compounds were verified using GC/MS, IH NMR, and FT-IR with support from 
elemental analysis. Evaluation of the effect of these cocaine analogs on the inhibition 
of dopamine uptake represented the biological focus of this project. Each of these 
series of compounds was evaluated in ligand binding and neurotransmitter uptake 
blockade assays as part of an ongoing research project at the National Institute of Drug 
Abuse. This program is designed to screen compounds for their usefulness in the 
treatment of cocaine abuse. None of the compounds in these two series demonstrated 
sufficient in vitro activity to warrant animal testing. 
vii 
A separate small series of unique compounds in which the 3-carboxylic acid moiety of 
benzoylecgonine was reduced to a primary alcohol and esterified with various 
nonsteroidal antiinflammatory drugs were synthesized. These compounds are potential 
prodrugs for the esterified NSAID and for benzoylecgonine. They will be evaluated 
for potential antirheumatic activity as part of a future study. 
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BACKGROUND AND SIGNIFICANCE 
Connective tissues diseases can be divided into a group of relatively uncommon, 
genetically determined disorders affecting the primary structure of this tissue and a 
number of acquired maladies where the connective tissues serve as the site of several 
distinctive immunologic and inflammatory reactions. These diseases are now taken to 
include the following: 1) rheumatoid arthritis (RA); 2) systemic lupus erythematosus; 
3) progressive systemic sclerosis; 4) polymyositis and dermatomyositis; 5) Sjogren's 
syndrome; 6) amy loidosis; 7) necrotizing arteritis and various other forms of 
vasculitis and 8) rheumatic fever. (1) This overview will focus primarily on RA and 
its treatment. Because of related drug treatment, the condition of osteoarthritis (OA) 
will also be discussed. 
Acquired connective tissue diseases have been classified as autoimmune disorders 
based on several criteria: 1) increased levels of serum immunoglobulin; 2) presence of 
specific immunoglobulins that react with certain serum proteins and various nuclear 
and cytoplasmic components of tissue, causing production of autoantibodies; 3) 
antigen-antibody complexes at sites of tissue damage; 4) accumulation of plasma cells 
and lymphocytes in affected tissue; 5) relief of symptoms with treatment of 
corticosteroids and/or other agents which inhibit production of autoantibodies; 6) 
association with other disorders known to be the result of problems with immunologic 
response( 1) . 
Osteoarthritis (OA) or degenerative joint disease is extremely common. It is a 
noninflammatory, progressive disorder of the movable joints with a pathological 
characterization which includes deterioration of the articular cartilage and formation of 
new bone in the subchondral areas and at the margin of the joint. It may occur as an 
inherent part of the aging process or secondary to joint injury, dysplasia, or other types 
of arthritis. 
The clinical features presenting during the development of degenerative joint disease 
include the excessive pressure on the joints associated with obesity and acquired or 
developmental structural abnormalities; various metabolic disturbances such as 
alkaptonuria and acromegaly; repeated joint hemorrhage; disordered proprioceptive sense 
and a genetic predisposition for certain forms of the disease( 1). 
Common complaints from patients with OA are joint pain, particularly on motion and 
weight-bearing joints; stiffness after periods of rest and aching in times of inclement 
weather. Physical examination reveals crepitation on joint motion, spasm or atrophy of 
the surrounding muscles, decreased range of motion, mal alignment of the extremity, and 
changes in the joint shape. 
Laboratory findings in OA are very much different from those associated with RA. 
Hematocrit, white blood cell count, and serum protein electrophoresis are usually 
normal. Erythrocyte sedimentation rate (ESR) is also normal while the latex 
agglutination test for rheumatoid factor (RF), a high molecular weight protein (IgM) 
found in increased levels in the serum of patients with rheumatoid arthritis, is negative. 
Synovial fluid analysis reveals little or no sign of inflammation( 1). 
Treatment objectives are relief of pain, restoration of function of the joint, and/or 
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prevention of avoidable disability or progression of the disease. Physical measures 
include daily rest periods with support of the affected joints. Correction of abnormal 
posture, avoidance of unnecessary walking and stair-climbing are advisable. Local 
measures include heat and exercises, while traction may be useful when there is muscle 
spasm. 
Drug therapy plays a relatively minor role on the treatment of OA except for the use 
of analgesics. Aspirin (600 mg three to five times daily) may be useful in conjunction 
with the measures listed above. Agents with greater toxicity are rarely warranted since 
they would have to be used on a long-term basis. 
Often surgical intervention is necessary for the relief of persistent pain and correction 
of severe deformity. The most common surgical procedures are debridement, 
arthrodesis, arthroplasty, osteotomy, and total joint replacement( 1). 
Rheumatoid arthritis is a chronic disease characterized by nonsuppurative 
inflammation of the diarthrodial (synovial) joints frequently combined with extra-articular 
manifestations such as vasculitis, pulmonary nodules, and chronic leg ulcers. Other 
symptoms include inflammation of the synovium accompanied by edema, vascular 
congestion, fibrin exudate, cellular infiltrate, and increased synovial fluid with increased 
turbidity. While the extent of the disease varies from patient to patient, it is 
characterized by a tendency toward spontaneous remission and exacerbation (1). 
The degree of articular disability depends mainly on the amount of damage done to 
the cartilage. Severe injury leads to denudation of large areas of bone and formation of 
adhesions between the joint surfaces with subsequent transformation of these adhesions 
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into bony connective tissue which can lead to total immobility of the joint. 
Physical evaluation of the disease in the early stages is crucial to eliminate other 
diagnostic possibilities and to beg'in a treatment regimen that will encourage improvement 
or even remission of the condition. The diagnosis is established by a typical clinical 
picture, histopathologic features, and certain characteristic laboratory findings such as 
anemia, elevated ESR, and hypergammaglobulinemia. A latex agglutination test reveals 
presence of rheumatoid factor. 
In 1987, a subcommittee of the American College of Rheumatology formulated the 
following set of criteria for the classification of RA shown in Table 1. A patient is 
diagnosed with RA if at least four of the seven criteria apply(2). These criteria must 
persist for at least 6 weeks. 
Although some patients are afflicted with a mild form of the disease that may last a 
relatively short time and cause little or no permanent damage, many others suffer from 
a recurrent or sustained condition causing a serious and permanent disturbance in joint 
function. At sites of involvement, swollen, boggy, joints occur as the result of intra-
articular effusion, edema at periarticular structures, and the overgrowth of the 
hyperplastic synovial membrane and variable degrees of periarticular fibrosis. Poor 
prognosis with respect to joint function include persistent disease greater than one year 
duration, age of onset less than thirty, sustained disease, and high RF titers. 
Table 1 
Criteria For The Classification Of Rheumatoid Arthritis 
Criterion 
Morning Stiffness 
Arthritis of three or more 
areas 
Arthritis of hand joints 
Symmetric arthritis 
Rheumatoid nodules 




Morning stiffness in and around the joints lasting at 
least one hour before maximal improvement. 
At least 3 joints have had soft-tissue swelling or fluid 
(not bony overgrowth alone) observed by a physician. 
The 14 possible joint areas are right or left PIP, 
MCP, wrist, elbow, knee, ankle, and MTP joints. * 
At least one area swollen (as defined above) in a 
wrist, MCP, or PIP. 
Simultaneous involvement of the same joint areas on 
both sides of the body (bilateral involvement of PIP, 
MCPs,or MTPs is acceptable without absolute 
symmetry). 
Subcutaneous nodules, over bony prominences, 
extensor surfaces, or juxtaarticular regions observed 
by a physician. 
Demonstration of abnormal amounts of serum RF by 
any method that has been positive in less than 5% of 
normal controls subjects. 
Roentgenographic changes typical of RA on AP hand 
and wrist roentgenograms, which must include 
erosions or unequivocal bony decalcification localized 
to or most marked adjacent to the involved joints 
(osteoarthrosis changes alone do not apply) 
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IC PIPs, proxImal Interphalangeal JOInts· MCPs, metacarpophalangeal JOInts· MTPs, 
metatarsophalangeal joints; AP, anteroposterior 
Rheumatoid arthritis is chiefly a disease of the joints, but often there are systemic 
manifestations involved. These features are apparently the result of underlying vasculitis 
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more commonly observed in patients with subcutaneous nodules and high RF titers. 
They include nodules in the lungs and the scleral coat of the eye, various nerve 
compression syndromes, ischemic ulcers characteristically located distally on the leg, and 
normocytic, slightly hypochromic anemia. 
The treatment regimen for a patient suffering from RA should be determined by the 
following factors: 1) the status of joint function, especially range of motion, 2) degree 
of disease activity, 3) the age, sex, occupation, and family responsibilities of the patient 
and his/her response to the disease, and 4) the results of previous treatment( 1) . 
The drug classes used the treatment of RA are as follows: 1) nonsteroidal anti-
inflammatory drug (NSAIDs), 2) immunosuppressive agents, 3) immunostimulatory 
drugs, and 4) disease modifying antirheumatic drugs (DMARDs). The type drug used 
is determined by the above criteria. 
The NSAIDs were initially developed as antipyretics. These drugs have survived to 
the present because they were found to be excellent analgesics for the relief of minor 
aches and pains. At lower doses, they act as simple analgesics, but at higher levels they 
have an effect on the other features of inflammation including the interruption of the 
arachidonic acid cascade by prostaglandin synthetase or cyclo-oxygenase inhibition(3,4). 
Inflammation is a complex reaction to an insult to the tissue. Following cellular 
damage, chemical mediators such as histamine, bradykinin, 5-hydroxytryptamine, slow-
reacting substance of anaphylaxis (SRS-A), chemotactic factors and prostaglandins are 
released locally. Phagocytic cells migrate into the affected area and contribute to the 
reaction by releasing lytic enzymes. The ability of NSAIDs to inhibit the production of 
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prostaglandins has been thought to account for their anti-inflammatory effects, but 
various mechanisms have been proposed including interference with cellular metabolism, 
release of inflammatory mediators, sodium and potassium ion transfers across cellular 
membranes, inhibition of chemical mediators other than prostaglandins, and stabilization 
of lysosomes (4). 
Salicylic Acid Derivatives: 
Aspirin (acetylsalicylic acid) (ASA)(Fig. 1) is the prototype compound in the 
salicylate category of the NSAIDs. Salicylates generally act by virtue of their salicylic 
acid content, although some effects of ASA are due to its capacity to acetylate proteins. 
Substitutions on the carboxyl or hydroxyl groups change the potency or toxicity of the 
compound. The ortho position of the hydroxyl group is important in the action of 
salicylates. Benzoic acid has many of the actions of salicylic acid while being much 
weaker. The effects of simple substitutions have been extensively studied and new 
salicylates are being synthesized (3). 
Salicylates are regarded as the standard by which other drugs are compared in the 
treatment of RA. In addition to the obvious benefits of analgesia, there is shown to be 
an improvement in appetite and an overall feeling of well-being. They also reduce the 
inflammation in joint tissues and surrounding structures when given in large doses for 
long periods to patients with active rheumatoid disease. These doses average from four 
to six grams daily, although some patients respond to less. Aspirin is thought to work 
specifically by inhibiting cyclo-oxygenase in the arachidonic acid cascade, causing 
inhibition of prostaglandin synthesis. Other salicylates have similar mechanisms of 
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action. 
The major toxicity with the high dose salicylate therapy needed to treat RA is the 
gastrointestinal distress and ulcerogenic properties of these compounds. Exacerbation of 
peptic ulcer symptoms, gastrointestinal hemorrhage, and erosive gastritis have all been 
reported. The gastric bleeding occurs in highest frequency with the use of salicylates 
that dissolve slowly and deposit as particles on the gastric mucosa. This problem may 
be avoided with the use of enteric coated products. The acute gastric irritancy of ASA 
may be associated with the carboxylic acid group. Modifications of the acidic 
characteristics of this group (perhaps by esterification) might also be a way to decrease 
the irritancy while retaining anti-inflammatory activity(5). For example, introduction 
of a 3-methyl group (adjacent to the phenolic OH group) in ASA and salicylic acid 
produces 3-methyl acetylsalicylic acid and 3-methyl salicylic acid, which displays a 
slower metabolic excretion. The 3-methyl group slows hydrolysis of the acetyl group 
and formation of the metabolite, 3-methyl salicylic acid. Aspirin derivatives modified 
on position 5 show greater antiinflammatory activity than ASA. 
Hepatotoxicity has also been seen in patients being treated for connective tissue 
disorders. Most patients are asymptomatic, with elevated hepatic enzymes the primary 
indicators of tissue damage. If symptoms do occur (such as hepatomegaly, anorexia, 
nausea, and jaundice), the salicylates should be discontinued due to the potential for fatal 
necrosIs. 
Diflunisal (Dolobid®)(Fig.l), 5-(2,4-difluorophenyl)salicylic acid is more potent than 
ASA with no apparent effect on blood platelet aggregation and is reported not to cause 
gastric bleeding. It is believed to inhibit production of prostaglandins (5). 
5-Pyrazolones: 
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The 5-pyrazolones are important because they led to the potent phenylbutazone class 
of NSAIDs. The anti-inflammatory activity of phenylbutazone (Butazolidin®)(Fig. 1) is 
somewhat less potent than that of indomethacin but greater than ASA. This activity is 
not mediated by the adrenal cortex, but more likely by peripheral mechanisms involving 
a decrease in capillary permeability. Phenylbutazone shows the same biochemical 
reactions as the other NSAIDs. Some of the mechanisms of action for ASA may also 
apply to phenylbutazone including uncoupling of oxidative phosphorylation, inhibition of 
prostaglandin synthesis, inhibition of the histamine-forming enzyme histidine 
decarboxylase, stabilization of lysosomal membranes, and inhibition of 
mucopolysaccharide biosynthesis. 
The therapeutic action of phenylbutazone is characterized by relief of pain, reduction 
of fever, and decrease in swelling, tenderness, and local heat. The initial daily dose for 
RA is 300 to 600 mg. divided into three to four doses. The drug has pronounced toxicity 
and should not be used for periods exceeding one week. 
Many modifications of the phenylbutazone structure have been made in attempts to 
increase activity and decrease toxicity. Because of the close relationship between the 
acidity and biologic activity of these derivatives, increasing the acidity will decrease the 
anti-inflammatory activity and sodium-retaining potency, but will greatly increase the 
uricosuric effects( 5) . 
Pheny lbutazone and the anti-inflammatory 3, 5-pyrazolidinediones, like the salicy lates, 
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possess ionizable protons (here enolic or potentially enolic). The process of ionization 
for the acidic protons in carboxylic and enolic acids may be compared as follows. 
Replacement of the hydrogen atom at C-4 of phenylbutazone by a CH3 to give 4-butyl-4-
methyl-l ,2-diphenyl-3 ,5-pyrazolidinedione destroys anti-inflammatory activity. This 
suggests that the enolizable beta-dicarbonyl system is essential. The butyl group at C-4 
may be replaced by a propyl group or allyl group without decreasing the anti-
inflammatory activity. The presence of a keto group in the gamma position of the butyl 
side chain produces the active compound, gamma-ketophenylbutazone. 
Activity is also retained when the para position of one or both benzene rings carries 
such substituents as methyl, chIoro, or nitro groups. Oxyphenylbutazone, a metabolite 
of phenylbutazone, contains a para-hydroxy group on one of these rings and is a potent 
anti-inflammatory agent. 
Replacement of one of the nitrogen atoms in the pyrazolidine nucleus with an oxygen 
yields an isoxazole analog with comparable anti-inflammatory activity. Compounds in 
which a cyclopentane or cyclopentene ring replace the pyrazolidine ring are inactive. 
Indomethacin: 
The aryl- and heteroarylacetic acid derivatives show high analgesic potency as well 
as anti-inflammatory activity. The prototype drug in this class is indomethacin 
(IndocinQP). (Fig. 1) The mechanism of action may be polyvalent and similar to the other 
acidic anti-inflammatory agents. These effects are not a result of stimulation of the 
production or release of corticosteroids. Indomethacin benefits RA patients by relieving 
pain, decreasing swelling and tenderness of the joints and increasing grip strength. 
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A systematic variation of the indole ring substituents on of indomethacin reveals the 
structure activity relationship (SAR) of this class of drugs. The COOH is necessary for 
anti-inflammatory activity since ~replacement with other groups decreases this activity. 
In addition, the more acidic the COOH group, the greater the potency of antirheumatic 
activity. Replacement of the I-arylacyl group by an arylalkyl function decreases activity, 
as does an aliphatic acyl or alkyl substitution at that position. A para halogen or 
equivalent (CF3 or SCH3) substituted for the I-benzoyl group provides the greatest 
activity. 
At the 2 position, a methyl group yields greater activity than an aryl group. At the 
alpha position on the side chain, a hydrogen and a methyl are in essence equal but an 
alpha, alpha-dimethyl or hydroxyl functional group decreases the potency. Position 5 
on the ring is most favorable for substitution. Methoxy, allyloxy, dimethylamino, acetyl, 
methyl, and fluoride functions show greater activity to hydrogen and chloride. 
In the indomethacin molecule, the 3-acetic acid side chain undergoes free rotation 
assuming different conformations. Of the alpha-methyl acetic acid analogs, anti-
inflammatory activity is displayed only by dextrorotatory enantiomers, which were later 
shown to have sinister (S) absolute configuration. 
The para-chlorophenyl group at N-I is also free to rotate and assume different 
conformations. The preferred isomer has the p-chlorophenyl group cis to the 
methoxyphenyl portion of the indole ring, yet it is not planar with the indole nucleus. 
This lack of planarity is due to the steric hindrance created by the 2-methyl group 
(necessary for high activity) and the hydrogen atom at position 7 which forces the para-
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chlorophenyl group out of the plane of the ring. The usual dose is 75 mg. daily or twice 
daily(5). 
Sulindac: 
The SAR studies of indomethacin and the l-arylindenyl isostere aided in the 
development of sulindac (Clinoril®)(Fig. 1). The heterocyclic nitrogen atom was 
removed resulting in an indene isostere that is an active compound lacking eNS activity 
and having less GI irritancy than indomethacin. Since this compound is insoluble in 
urine, further modification was necessary to allow clinical use. Substitution of a fluoride 
and methylsulfinyl group increases the solubility while retaining the potency. The anti-
rheumatic oral dose is 150 to 200 mg twice daily. 
Diclofenac: 
One of the most widely used NSAIDs, diclofenac (Voltaren@), possesses structural 
characteristics of both arylalkanoic acid and anthranilic acid classes of anti-inflammatory 
agents(Fig.2). It displays anti-inflammatory, analgesic, and antipyretic properties. It has 
three possible mechanisms of action: 1) inhibition of the arachidonic acid 
cyclooxygenase system resulting in decreased production of prostaglandins and 
thromboxanes; 2) inhibition of the lipooxygenase pathway which decreases production 
of leukotrienes; and 3) inhibition of arachidonic acid release and stimulation of its 
reuptake thereby decreasing arachidonic acid availability. It is indicated for the treatment 

























Etodolac (Lodine~)(Fig. 2) has been promoted at the first in a new chemical class 
of anti-inflammatory agents, the pyranocarboxylic acids. Although there is a two carbon 
separation between the carboxy lie acid function and the heteroaromatic ring, it still 
displays the structural characteristics similar to the hetero-arylacetic acids. It is 
recommended for the management of OA, and for use as an analgesic. Etodolac also 
possesses some antipyretic activity as well. At 2.5 to 3 times the effective dose, it 
produces less GI bleeding than indomethacin, ibuprofen, or naprosyn, giving this 
compound a potential therapeutic advantage in patients prone to GI distress. 
Etodolac's primary mechanism of action is inhibition of the boisynthesis of 
prostaglandins at the cyclooxygenase step, with no accompanying inhibition of the 
lipoxygenase system. It is recommended for the treatment of the signs and symptoms 
of OA (800-1200 mg/day) and for pain management (200-400 mg every six to eight 
hours as needed). 
Tolmetin: 
Tolmetin (Tolectin~)(Fig. 2) is the major drug in the pyrrolacetic acid derivative 
class. It is similar in structure to indomethacin and contains the three moieties of the 
indomethacin molecule considered necessary for activity: the carboxyl function, an out-
of-plane phenyl ring, and the flat indole ring system. The latter was replaced in tolmetin 
by a pyrrole ring. The dose of tolmetin equivalent to 4000 mg of ASA in RA is 1260 
mg daily (5). 
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Phenyl-alpha-methylacetic acids: 
The phenyl-alpha-methylacetic acid derivatives are a widely used class of anti-
inflammatory agents. The most commonly prescribed drugs in this category are ibuprofen 
(Motrin@), fenoprofen (Nalfon<1P), ketoprofen (Orudis<1P), flurbiprofen (Ansaid@), ketrolac 
(Toradol@), and oxaprozin (Daypro<1P). These drugs are chemically related to 
indomethacin, tolmetin, and naproxen. 
Ibuprofen (Fig. 2) also inhibits prostaglandin formation. It may also cause less 
gastric distress than ASA. The alpha-methyl group on the acetic acid moiety causes an 
increase in potency. The antiinflammatory activity is found exclusively in the (S)-( +) 
isomer; this relationship is maintained throughout the ary lacetic acid series. These 
isomers are the more potent inhibitors of prostaglandin synthetase. A dose of 1600 to 
2400 mg per day is as effective as ASA in RA (5). 
Fenoprofen (Fig. 2) differs from ibuprofen only in containing an meta-phenoxy rather 
than the para-isobutyl group In addition to its inhibition of prostaglandin synthesis, 
fenoprofen inhibits the rate of collagen-induced platelet aggregation, shows in vitro 
activation of the fibrinolytic system, stabilizes lysosomal membranes, and inhibits 
phagocytosis and complement functions (5). 
The isomer of fenoprofen in which the phenoxy group is meta to the propionic acid 
moiety is more active than either the ortho or para isomers. Optimum separation of the 
COOH from the aromatic group is one methylene unit. Alpha-substitution of the acetic 
acid group usually increases potency, with the methyl group (fenoprofen) being highest 
and the n-butyl group being nearly equivalent to the unsubstituted acid. Alpha-
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substitution with any branched alkyl chain is detrimental. Ester, amide, amine, and 
alcohol analogs are all relatively potent, possibly by conversion to fenoprofen in vivo. 
Although fenoprofen has been resolved into its enantiomers and apparently has no 
significant anti-inflammatory or analgesic activity differences between either isomer or 
the racemic mixture. This may, however, be due to a rapid inversion of the (R)-( -) to 
the (S)-( +) isomer. This conversion has been shown to occur in humans. The (S)-( +) 
isomer has been shown to be 35 times more potent in vivo than the other isomer for 
inhibition of the cyclooxygenase pathway. For treatment of RA, the recommended 
dosage of fenoprofen is 300 to 600 mg three to four times daily (5). 
Ketoprofen (OrudisQP)(Fig. 2) inhibits the synthesis of leukotrienes and leucocyte 
migration into inflamed joints in addition to inhibiting the biosynthesis of prostaglandins. 
By stabilizing the lysosomal membrane during inflammation, it decreases tissue 
destruction. Antibradykinin activity has also been observed with ketoprofen. This drug 
is indicated for the long-term management of RA and OA (in doses of 150-300 mg/day), 
mild to moderate pain, and primary dysmenorrhea. 
Other carboxylic acids and derivatives: 
During screening of the pharmacologic properties of substituted phenylalkanoic acids, 
the most potent were found to be the substituted 2-(4-biphenyl)propionic acids. More 
detailed studies indicated that flurbiprofen (Ansaid4P) (Fig. 2) had the most desirable 
therapeutic profile. An inhibitor of PG synthesis, flurbiprofen has anti-inflammatory 
activity 536 times more potent than ASA in studies done on adrenalectomized rats. It 
is indicated for the treatment of RA or OA in doses ranging from 200-300 mg/day. 























Ketrolac (Toradol®)(Fig. 3), a prostaglandin synthesis inhibitor, represents a cyclized 
heteroaryl propionic acid with the alpha-methyl group fused to a pyrrole ring. It is 
indicated only as a peripheral analgesic although it possesses anti-inflammatory and 
antipyretic activity as well. A 15 to 30 mg dose of ketrolac produces analgesia 
equivalent to a 12 mg dose of morphine, and has therefore become an alternative to 
opioid analgesia. It is not indicated for the treatment of rheumatic conditions due to the 
often severe GI distress that may occur with oral dosing. 
Oxaprozin (DayproQP) (Fig . 3), although not formally a propionic acid derivative of 
the alpha-methylacetic acid type, is similar to that class of NSAIDs and will be discussed 
as such. A prostaglandin synthesis inhibitor, oxaprozin exhibits antipyretic, analgesic, 
and anti-inflammatory acitvity. It was approved by the FDA in 1992 for the short- and 
long-term treatment of RA and OA with a recommended dose of 1200 mg/day. 
Naproxen (NaprosynQP) (Fig. 3), the main compound in the napthyleneacetic acid 
derivative group, is designed to include the chemical features found in the pre-existing 
anti-inflammatory drugs. These are an aromatic group, and acidic group, and a side 
chain. It does not contain the nitrogen atom associated with some of the side effects. 
Modification of the side chain on the napthylene ring has shown that the 6 position was 
the most active. Also when the side chain is larger than OCH3 or SCH3, activity is 
reduced. The COOH group may be replaced by a hydroxyl or aldehyde group and retain 
function. The recommended initial dose is 250 mg twice daily. Daily doses exceeding 
750 mg are not recommended(5). 
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N -arylanthranilic acids: 
A new class of NSAIDs was developed utilizing bioisosterism. The N -arylanthranilic 
acids (fenamic acids) are nitrogen isosteres of salicylic acid. Their anti-inflammatory 
activity and analgesic properties show little advantage over the salicylates and interest in 
their development has diminished. Only two of these compounds, mefenamic acid 
(Ponstel®)(Fig. 3), used primarily for analgesia, and meclofenamate (Meclomen®) (Fig.3) 
are marketed in the United States. Meclofenamate is dispensed in a dosage of 200-5400 
mg/day in divided doses for the treatment of RA and OA. 
Oxicams: 
The oxicams are a relatively new class of NSAIDs that are not carboxylic acids. 
These compounds are exemplified by piroxicam (Feldene®) (Fig. 3). It is a potent 
inhibitor of prostaglandin biosynthesis through inhibition of the cyclooxygenase step of 
arachidonic acid metabolism, a mechanism of action similar to other NSAIDS. 
Piroxicam can cause severe GI distress. Peptic ulceration and GI hemorrhages have 
been reported. The recommended dosage for RA is 20 mg daily or 10 mg twice daily. 
The 3-carboxamide substituent on the 1,2-benzothiazine nucleus contributes to good 






















Disease Modifying Antirheumatic Drugs 
Disease modifying antirheumatic drugs (DMARDs) are a heterogeneous group of second-
line agents used in the treatment of RA. They are remission-inducing agents or slow-
acting anti-inflammatory medications . For the most part, these were initially developed 
for other disease processes and later applied to RA. In short-term randomized trials , 
second-line agents are more effective than NSAID therapy only , and modify the 
symptoms of disease activity , but do not necessarily affect a cure (6). DMARDs also 
lack immediate analgesic or anti-inflammatory effects and can possibly cause severe 
adverse effects. They can take weeks to months to produce results and are usually given 
concurrently with a faster-acting NSAID. 
4-Aminoquinolines: 
The 4-aminoquinoline antimalarial agents have been used since 1951 to treat RA. 
Hydroxychloroquine (Plaquenil®)(Fig. 4) is indicated in the treatment of acute and 
chronic RA in patients with disease states refractive to other less toxic antirrheumatics. 
A daily oral dose of up to 400 mg has been found to be effective (5). Clinical response 
can be anticipated within three to six months after initiating therapy with 40 to 60 % of 
patients able to expect a beneficial response. Patients with earlier and milder disease 
have the greatest potential for a positive response on antimalarial therapy. The most 
common side effect is GI intolerance as signified by nausea, epigastric discomfort, 
anorexia, and vomiting. Infrequently, headaches, dizziness, and mental confusion may 
occur. Dermatologic complications are rare, but cases of exfoliative dermatitis have been 
seen. Neuromyopathy may occur with therapeutic doses and appears as proximal 
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myopathy, neuromyopathy, or cardiomyopathy. Corneal deposits occur in up to 50 % of 
patients. These do not generally cause visual impairment, but are reversible and not a 
contraindication to sustained therapy. Routine (every 3 months) exams are recommended 
to detect early ophthalmological changes. 
Gold Compounds: 
The gold compounds are often considered the therapy of choice when a drug must 
be added to the ASA regimen. Gold compounds are currently used in the treatment of 
early, active RA that progresses despite therapy with aspirin-like drugs. 
Three gold compounds in major use are water-soluble gold sodium thiomalate and 
aurothioglucose (Solgaral®)(Fig. 4), which are administered intramuscularly; and orally 
administered, lipid-soluble auranofin (Ridaura®)(Fig. 4). These drugs have several 
possible mechanisms of action. Aurothiomalate inhibits lysosomal enzymes, possibly by 
a reversible binding to sultbydryl groups. Gold compounds also alter the properties of 
collagen in rats. In vitro, they inhibit prostaglandin synthesis (5). 
Therapeutic response occurs in approximately 40 to 60% of patients, although 20 
to 30 weeks of treatment may be necessary before relief is clinically perceptible. 
Parenteral gold is administered weekly at 50 mg/week for 20 to 30 weeks. Once clinical 
response is noted, the injections are decrease to once every three weeks, then once every 
two weeks, and finally monthly to arrive at a maintenance regimen of approximately 25 
to 50 mg given every three to four weeks. Concurrent administration of salicylates or 
other NSAID is necessary during the first few months of gold therapy to provide 
symptomatic relief. 
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The adult oral dosage of auranofin is 6 mg daily. If no response is seen after six 
months, the dose may be increased to 9 mg daily. If still no response seen after three 
months at the higher dose, the drug should be discontinued (5). The onset of action for 
oral gold is three to nine months. 
Adverse experiences occur in about 40 % of patients using 1M gold. Mucocutaneous 
reactions and stomatitis are most common. Proteinuria and nephrotic syndrome, due to 
development of membranous glomerular nephropathy, may occur. Of hematologic 
toxicities with 1M gold, eosinophilia is fairly common, and agranulocytosis or aplastic 
anemia, although uncommon, can be life-threatening (6). Regular urine and blood tests 
for renal and hematologic abnormalities are recommended. Oral gold is primarily 
excreted through the GI tract, and because of this, the main side effect is diarrhea. Skin 
rashes, hematologic toxicity and proteinuria are also seen occasionally (6). The chelating 
agents such as dimercaprol or penicillamine have been used to enhance excretion and 
control the toxic effects of these compounds (5). 
Penicillamine: 
Penicillamine (Cuprimine~)(Fig. 4) is indicated in patients with severe, active RA 
who have not responded to other therapy. It is similar to the gold compounds and may 
retard the progression of bone erosions. The mechanism of action is not known but may 
involve improvement of lymphocytic function. Penicillamine is neither anti-inflammatory 
nor cytotoxic. The drug should be given on an empty stomach and at least one hour 
apart from any other medication, food, or milk to maximize absorption and decrease the 
chance of inactivation by metal binding (5). The onset of action may be delayed as much 
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as six to nine months. The maximum dose for RA is 750 mg to 1000 mg daily. Low 
doses (125-250 mg) of the drug are used initially and slow-dose titration done to decrease 
the potential for side effects. 
Penicillamine exhibits a toxicity profile similar to 1M gold, including mucocutaneous 
reactions, proteinuria, nephrotic syndrome, leukopenia, thrombocytopenia, and in rare 
cases, aplastic anemia. 
Azathioprine: 
Azathioprine (Imuran®)(Fig. 4), a purine analog, prevents the conversion of 
purine bases by suppressing the first step of de novo biosynthesis of guanine and 
adenosine. It is the most commonly used immunosuppressive drug in RA (7). Although 
the mechanism of action is not understood, azathioprine has been shown to be effective 
at doses of 1.0 to 2.5 mg/kg/day. The onset of action is 12 to 24 weeks. The most 
common toxicity associated with the drug is gastrointestinal, including nausea, anorexia, 
and rarely, vomiting and pancreatitis. Hematologic toxicity including leukopenia, 
thrombocytopenia, and anemia may occur and are generally dose dependent (6). 
Methotrexate: 
Methotrexate (MTX) (Rheumatrex®)(Fig. 5), an antifolate drug, has gained wide 
acceptance in the treatment of RA. It is used primarily in patients that have failed to 
respond to gold therapy; however, there is an increased interest in using MTX earlier in 
the disease prior to gold therapy. The mechanism of action of MTX in relation to RA 












































and in vitro responses to mitogen and antigen proliferation have not demonstrated global 
immunosuppression. In vitro RF synthesis was slowed by MTX therapy. Possibly a 
more promising area of research involves the effects of MTX on proinflammatory 
mediators. A consistently significant decrease in leukotriene B4 release from stimulated 
WBCs ex vivo has been reported after MTX therapy (6). 
The most common adverse reaction is GI intolerance, e.g. anoreXIa, nausea, 
vomiting, diarrhea, and unexplained weight loss. Stomatitis may also occur as well as 
alopecia, erythema in response to UV light, and urticaria. Central nervous system 
toxicity including headaches, dizziness, depression, and mood alteration have been noted. 
Bone marrow toxicity may occur and is usually associated with these risk factors: renal 
insufficiency, folic acid depletion, drug overdosages, and concomitant use of 
sulfamethoxazole/trimethoprim. Renal insufficiency of a concurrent or pre-existing 
nature may lead to toxic levels of the drug, because MTX is excreted exclusively by the 
kidney. 
Cyclosporine: 
Cyclosporine A (Sandimmune~)(Fig. 5) has been used as a therapeutic agent in a 
variety of autoimmune and inflammatory illnesses. Various studies have been done at 
different dosages to determine its efficacy in RA. The dosages ranged from 1 to 10 
mg/kg/day. All studies showed marked improvement in disease parameters; however, 
side effects were significant in each. These include hypertension, fatigue, 
thrombocytopenia, significant renal dysfunction (e.g. increased serum creatinine), GI 
intolerance, and skin rash. The renal toxicity in particular limits the therapeutic 
applications of cyclosporine A in nontransplant situations (6). 
Sulfasalazine: 
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Sulfasalazine (Fig. 5) was developed over 50 years ago specifically for RA. The 
most common side effect is GI intolerance. Hematologic toxicity, including hemolytic 
anemia, folate deficiency, thrombocytopenia, leukopenia, and aplastic anemia are also 
seen. Rarely, reversible oligospermia, fever, rash, exfoliative dermatitis, and 
pneumonitis may develop (6). 
Cyclophosphamide: 
Cyclophosphamide (Cytoxan®)(Fig. 5), an alkylating agent, has been shown to inhibit 
both humoral and cellular immunity and to suppress passive transfer of cellular 
immunity. The exact mechanism(s) of action is/are unknown. As an alkylating agent, 
cyclophosphamide interferes with cellular metabolism and exerts a cytotoxic effect 
independent of phases of the cell cycle. It appears not only to interfere with early events 
in the generation of the immune response by also to have a direct effect on Band T 
effector cells. Among various studies, the incidence of improvement of RA patients 
treated with cyclophosphamide ranged from 75 to 100 % . Patients on this therapy 
appeared to show less radiological joint deterioration than patients treated with gold. 
The actual mechanism of action of cyclophosphamide in RA is not understood. The 
drug appears to exert suppressive effects on some parameters of the immune response 
which may be of primary importance. There is a lack of correlation between therapeutic 
efficacy and immune status by any of the parameters measure to date. Studies have 














in both serum immunoglobulin and RF titers are also seen. Adverse side effects of 
cyclophosphamide include alopecia, hemorrhagic cystitis, azoospermia, and sustained 
lymphopenia (7). 
A number of novel therapies are currently under development. A significant amount 
of emphasis is directed toward newer inhibitors of arachidonic acid metabolism, 
specifically inhibition of the 5-lipoxygenase pathway or drugs that inhibit the 
cyclooxygenase and 5-lipoxygenase pathway. These drugs are anticipated to have less 
GI toxicity than the traditional cyclooxygenase inhibitors. Compounds that affect specific 
cytokines, e.g. interleukin-l are also being developed. Monoclonal antibodies directed 
against specific cell lines and compounds that inhibit proteolytic enzymes such as 
collagenase are being studied as well. Clinical trials have been initiated to test more 
selective immunosuppressive agents (6). 
Anecdotal evidence has shown that insufflation of a modified preparation of cocaine 
has been found to provide substantial benefits in the treatment of RA and in slowing the 
progress of the disease. One such incident involves identical twins with RA. One was 
suffering from symptoms of the advanced stages of the disease while the other was 
symptom free. No traditional treatment seemed to be effective. The patient was deemed 
near terminal and was given cocaine to potentiate his pain medication. Within two 
weeks, he had no sign of active RA. Upon further questioning, the asymptomatic twin 
admitted to be a recreational user of cocaine (8). Treatment of other patients with 
similar disease profiles showed similar results (9). 
These non-controlled studies led to the development of a topical preparation of 
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cocaine derivatives. It has been tested in Phase II clinical trials to determine efficacy in 
treating decreased range of motion due to painful shoulder, acute back sprain, or 
resulting from wearing a cast on a limb for an extended period of time. The results of 
these trials indicate that this preparation specifically improves restricted range of motion 
in painful shoulder and acute back sprain and is effective in improving range of motion 
following cast removal. 
The results of these clinical trials corroborate the earlier anecdotal evidence. 
These compounds appear to be the origin of new drug entities that could alleviate the 
severest symptoms of RA and related conditions and even potentially arrest the progress 
of the diseases. Based on this possibility, the goal of this project is to utilize a logical 
structure activity relationship approach which leads to the development of the active 
agents. This approach includes developing proper synthetic procedures for and, 
structural analysis and biological screening of these compounds for potential activity. 
Cocaine is the starting material for the clinically evaluated topical preparation. This 
product is composed of a variety of cocaine derivatives. Consequently, the compounds 
proposed represent logical modifications of cocaine. A review of the chemistry, 
pharmacology and metabolism of cocaine follows. 
COCAINE: STRUCTURE AND METABOLISM 
Cocaine (I), (-)2(R)-carbomethoxy-3(S)-benzoxy-l (R)-tropane or 3-benzoyloxy-8-
methyl-8-azabicyclo[3 .2.1]octane-2-carboxylic acid, methyl ester (11), a natural alkaloid, 
is obtained from the leaves of Erythroxylon coca, a plant species found in South 
31 
America. Cocaine (I) has two basic types of pharmacological properties. It can act as 
both a local anesthetic and CNS stimulant (10,11,12). Its conformation consists of the 
piperidine nucleus in the chair form with the carboxymethyl side chain on C-2 in the 
axial position and the benzoyloxy group on C-3 equatorial (Fig. 6). The molecule has 
four chiral centers on C-l, C-2, C-3, and C-5, giving rise to eight possible pairs of 
enantiomers. However, with C-l and C-5 restrictec! to the cis position, and the fusion 
of the nitrogen bridge, only four pairs are actually possible. Three of the four pairs have 










Cocaine (I) is rapidly metabolized via hydrolysis by plasma esterases and liver 
enzymes or non-enzymatic hydrolysis to the water soluble products, methylecgonine (II) 
(ME) and benzoylecgonine (III) (BE) (11,12). ' The molecule is also N-demethylated to 
norcocaine (V) (NC), a phannacologically active metabolite (10,11,13,14) (Fig. 7). 
COaCH) 
6 07.-<0) OH 
0 
cocaine ..., .J 
(I) methylecgonine 
(II) 
















Cocaine (I) possesses multiple actions on the central and peripheral nervous 
systems. Peripheral effects include potent local anesthetic properties as well as indirect 
catecholaminergic actions, and stimulatory effects in the central nervous system (16). 
Local Anesthetic Actions 
When applied to the skin or mucous membranes, cocaIne (I) inhibits the 
conduction of sensory impulses within the neuronal membrane by reacting with the 
neuronal membrane to block ion channels (16-19). Membrane-bound calcium plays an 
important role in the initial phase of membrane depolarization necessary for the 
generation of nerve impulses. Cocaine (I) may inhibit this release of bound calcium or 
replace these ions at the site of action, thereby stabilizing the membrane to 
depolarization. This prohibits the production of the threshold potential required to permit 
the activation of the sodium ion channels which in tum prohibits the transmission of 
nerve impulses (17). 
The other proposed route for cocaine's (I) actions as a local anesthetic involves 
disruptions in the neuronal membrane lipids, which increases the surface pressure of 
these membranes, causing closure of ion pores which restrict openings in the sodium ion 
channels, thus reducing ion permeability, resulting in the inhibition of nerve irnpulse 
transmission (16). 
Stimulant Properties 
The central and peripheral stimulant activities of cocaine (I) are due to the indirect 
catecholaminergic action that enhances the effects of nerve impulse transmission (16) . 
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Centrally, cocaIne (I) acts on the nerve terminals for norepinephrine (NE)(12, 16), 
dopamine (DA) (16), or serotonin (5-HT) (12). The peripheral actions are due to the 
potentiation of NE at the adrenergic terminals of the sympathetic branch of the autonomic 
nervous system (17). 
Peripheral effects. Due to cocaine's (I) effects on NE, both the excitatory and 
inhibitory responses of sympathetically innervated organs are potentiated (17). The 
symptoms include tachycardia, vasoconstriction, hypertension, mydriasis, hyperglycemia, 
increased rate of glycogenolysis in the liver and muscles, liberation of fatty acids from 
adipose tissue, increased secretion of sweat glands, contraction of pilomotor muscles in 
the skin, stimulation of salivary glands, increased water and potassium secretion, and 
elevated body temperature (due to increased muscular activity and vasoconstriction) 
(12,17). Cocaine (I) blocks the reuptake of NE at the synaptic cleft and stimulates its 
release from presynaptic vesicles (17). Due to this, tyrosine hydroxylase, the rate 
limiting enzyme in catecholamine synthesis, is activated. This neurotransmitter reuptake 
blockade increases alpha- and beta-adrenergic effects when the drug is used initially or 
acutely. Chronic use leads to a greater increase in alpha and beta receptor density with 
eventual sensitization (17). The overall effect is a decrease in NE levels at the peripheral 
adrenergic receptors. 
Central effects. Both the euphoric and non-euphoric effects exhibited by cocaine 
(I) are due to its action on NE, DA, and 5-HT in specific sites in the brain. The noo-
euphoric effects are speculated to be caused by cocaine's (I) indirect action on NE and 
5-HT. The symptomatic manifestations include anxiety, hypervigilance, suspiciousness, 
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and persecutory fears. The euphoric effects are exhibited primarily in the initial phase 
of use and are thought to be the result of cocaine's (I) indirect action on DA (12,16). 
They include mood elevation, a 'sense of increased self esteem, well-being, and mental 
and physical capacity. Appetite and need for sleep are decreased and sexual interest is 
heightened. Although the mechanism for the euphoria is not understood, it is speculated 
that cocaine blocks the reuptake of DA and also facilitates its release(12, 17). These 
actions trigger the synthesis of DA and lead to an increase in the number of DA 
receptors and also an increase in receptor sensitivity. Ultimately, inhibition of DA 
vesicle binding occurs and causes the intracellular metabolism of more DA. Chronic use 
of cocaine (I) leads to decreased concentrations of DA in the brain(12,17). This 
depletion of DA can cause intense dysphoria, craving and symptoms of withdrawal. 
N euroendrocrine dysfunction, such as hyperprolactinemia is also thought to result in this 
situation( 10). Centrally mediated responses due to dopamninergic activity include 
increases in locomotor activity, body temperature, respiratory rate, alertness and 
loquaciousness; and decreases in appetite and fatigue (12,16). There is no doubt that the 
psychomotor stimulant effect is partly due to the ability of cocaine (I) to block reuptake 
of all central catecholamines (12,17). 
Higher doses cause tremors and eventually tonic-clonic seIZUres which are 
possibility due to stimulation of the lower motor centers and an increase in the sensitivity 
of the cord reflexes. Continued use in elevated doses can be lethal due to depression 
of the medullary centers and respiratory failure (17). 
Serotonin is a central neurotransmitter also capable of causing effects similar to 
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those of DA, as well as endocrine function. Cocaine (I) blocks 5-HT reuptake and 
facilitates its release, which will result in an overall decrease in the concentration of 5-
HT, but just how cocaine (I) influences the functions of 5-HT is not clear (12,17). 
STRUCTURE-ACTIVITYRELATIONSHIPSANDPHARMACOLOGICALEFFECTS 
Local Anesthetic Effects 
The activities of cocaine (I) have been compared to benzoylecgonine (III) (BE), 
methylecgonine (II) (ME), ecgonine (IV) (E), and the stereoisomers (+ )pseudococaine 
and (-) pseudococaine [the C-2epimers], and (+/-)allococaine [the racemic C-3 epimer], 
as well as (+ / -)allopseudococaine. All show varibility in both local anesthetic action 
(LAA) and influence on the sympathomimetics (17). 
Methylecgonine (II) and ecgonine (IV) are both inactive in regard to LAA and have 
no effects on sodium channels(17). This may be due to the absence of the benzoyl group 
at C-3. Norcocaine (NC) (V) and (+ )pseudococaine exhibit more local anesthetic 
activity than cocaine (I), while ( + / -)allococaine and BE (III) are less potent than cocaine 
(I) (17). Removal of the ester linkage between the heterocyclic and aromatic rings on 
the molecule decreases the LAA (20,21). 
( + / -)Pseudococaine has increased interaction with the sodium channels and 
increased LAA (21). Structural requirements for observable LAA include the benzoyloxy 
group equatorial at C-3, the ester group at C-2 either axial or equatorial, and the 
presence of a secondary or tertiary amine function. Also, the substituent on C-3 has 
more influence than the C-2 on sodium channel interaction (20). 
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Central Stimulatory Effects 
The sympathomimetic activities of cocaine (I) and its cogeners do not correlate 
with the potential effects on the sodium channel (20). In studies, cocaine (I) and NC (V) 
are active both IV and intracisternally (17,19), while BE (III) and benzoylnorecgonine 
(VI) (BNE) are active after intracisternal administration only. Ecgonine (IV) and ME 
(II) are inactive via both routes. The effects of BE (III) and BNE (VI) by intracisternal 
injection are dose dependent and differ in nature from those seen after injection of 
cocaine (I) and NC (V) (17). 
Structurally, the diester is required for both LAA and absorption across the blood 
brain barrier. The metabolites with the carboxyl groups at C-2 [BE (III), BNE (VI)] 
exhibit stimulatory activity once they are in the CNS. The secondary amine such as NC 
(V) has greater stimulatory activity than the tertiary amine(17). 
Calcium Binding Effects 
Cocaine (I) and its metabolites have been studied in an attempt to parallel the 
observed eNS effects with the calcium binding activity of the compounds. Calcium is 
known to participate in several neuronal functions at the membrane level, such as 
neuronal excitation. Increased calcium ion concentration greatly increases the threshold 
of nerve stimulation while decreased calcium increases nerve excitability(19). Due to the 
complexation of calcium by cocaine (I) or its metabolites and subsequent mobilization of 
neuronal-membrane bound calcium ions which decreases the availability of the ion to 
sites controlling transmembrane permeability to sodium ions, the excitatory effects of 
cocaine and its metabolites may be greatly influenced(19). 
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Neuronal Uptake Activity 
The structure activity relationship of cocaine (I) and its cogeners has been 
evaluated in light of the structUral requirements for interaction with DA and 5-HT 
neuronal uptake sites in mouse brain (20). Removing the ester linkage between the 
pheny I and tropane ring did not decrease the affinity for either cocaine (I) binding sites 
or the monoamine uptake sites. Conformation has significant effects, as pseudococaine 
(C-2 epimer) and allococaine (C-3 epimer) show decreased potency with allococaine 
being the least potent of the two, suggesting that the position of the substituent at C-2 is 
more important in DA and 5-HT uptake. Removing the C-2 substituent decreases this 
activity greatly, although less than removal of the methyl ester at C-2 [BE (III), E (IV)] 
which inactivates the molecule. This may be due to the reduced lipophilicity and 
therefore decreased affinity. Differences in activity are also seen in the dextro and leva 
isomers of some of the modified compounds, revealing that stereoselectivity is a factor 
for both sites(20) . 
PROPERTIES PERTAINING TO ABUSE POTENTIAL 
The most relevant effects of cocaine (I) pertaining to drug abuse include its ability 
to produce euphoria and its reinforcing properties. In addition, cocaine (I) has properties 
similar to other drugs of abuse such as withdrawal and craving (22). 
Of the sites of action of cocaine (I) in the eNS, it is the dopaminergic pathway 
that seems to be responsible for cocaine's (I) reinforcing properties. The theory for this 
is the "Dopamine Hypothesis" (25). This hypothesis puts forth the premise that cocaine 
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(I) binds at the DAT and inhibits neurotransmission reuptake in the mesolimbocortical 
pathways and thereby causes reinforcement. Ligand binding studies present evidence that 
binding at the DAT is inhibited by cocaine (I) and by related compounds at potencies of 
the same compounds in behavioral studies of drug reinforcement (26). Since ligand 
binding with other receptors do not show such a correlation, cocaine's (I) reinforcing 
properties can be specifically related to binding at the D AT. 
Pharmacological studies of drug self-administration support the hypothesis (28-30), 
although there is the possibility that cocaine (I) has activity other than the inhibition of 
DA uptake. Pharmacokinetic effects probably playa significant role since drugs entering 
the brain more rapidly are more likely to induce dependence (31) and cocaine is known 
to cross the blood brain barrier and quickly occupy receptors(32,33). 
Specific evidence supporting the hypothesis include the following(24): 
1. The potency of various cocaine-like compounds in maitaining self-
administration can be predicted by each compounds' affinity for the DAT but not 
predicted by its affinity for NE or 5-HT transporters. 
2. A lesion of the dopaminergic innervation of the nucleus accumbens disrupts 
self-administration of cocaine (I), but similar lesions in noradrenergic system or DA 
terminal in the striatum have no effect. 
3. Cocaine (I) craving in humans is decreased by indirect agonists of DA 
(34,35). 
4. The increase in extracellular DA levels in the brain following cocaine (I) 
administration has a time course similar to the euphoria reported by the subjects taking 
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cocaine (I). 
There is some controversy as to the type of binding that occurs between cocaine and 
its binding site on the D AT. Evidence supports both competitive and allosteric binding. 
Several compounds including cocaine (I) have been shown to competitively inhibit DA 
uptake in striatal tissue (37,46). Other study results support the hypothesis of 
allosterism; that cocaine (I) inhibits the DAT by binding to a site other that the DA 
recognition site on the transporter(38,39,40). Also, the fact that DA is more potent that 
cocaine (I) in inhibiting [3H]DA accumulation in vitro, but is much less potent than 
cocaine in displacing specifically bound [3H]-(R)-cocaine is consistent with the ideas of 
different recognition sites (41, 42). 
Two early studies reported evidence supporting a single PH]-R-cocaine binding site 
to mammalian brain (39,40). Present evidence has demonstrated that there are at least 
two binding sites for (R)-cocaine associated with the DAT, one with high affinity and one 
with low affinity. The two sites have kd=0.1-210 nM and 2.57 nM to 26.4 p,M, 
depending on the radioligand, tissue source, species and buffer used. One key question 
pertains to whether the two cocaine (I) binding sites are related to two distinct proteins, 
distinct sites on the same protein or to two different affinity states of one protein (42). 
Since clinical effects of cocaine (I) are seen at plasma concentrations of less than 1.0 
/-tM (40), the high-affinity site may be the most physiologically significant receptor site, 
although quite a few of the low-affinity sites will be occupied at this concentration as 
well. Whether this site alone is relevant to cocaine's (I) abuse potential or whether both 
sites playa role in the reinforcing properties of cocaine (I) is unknown. 
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An understanding of the SAR of cocaine (I) is necessary to gain an insight into the 
interactions of cocaine (I) with the DAT that seem to be implicated in the CNS effects 
of the compound. A comparison- of the effects of structural variation on the IC50 values 
for the inhibition of binding and DA uptake at the DAT is a means by which this 
understanding may be gained. The results of several SAR studies have been reported 
(2, 17-19) . The conclusions include the following requirements: 
a) (R)-configuration of cocaine (I) structure (2,17); 
b) a beta substituent (17, 18) at C-2, preferably a carbomethoxy group (17); 
c) a benzene ring at C-3, an ester link in this position is not required (17). 
Substitutions at C-2 (19), C-3 (17), N-8, the effects of stereochemistry (2), and 
position of the ring nitrogen (18) have been further elucidated. 
An analysis of the effect of a single structural parameter on the activity of cocaine-
like compounds at the DAT was done and the following observations were made (27): 
1) The largest factor in activity is configuration. Inversion of configuration decreases 
activity by a factor of up to 1000. This effect is not carried over into cocaine's (I) less 
active isomers. The activities of (S)-pseudococaine, (S)-allococaine and (S)-
allopseudococaine are only 1.2-7.4 times smaller than those of the R analogues. 
2) The second largest influence on activity is substitution at C-2. Replacement of 
the carbomethoxy group by H, COOH, or by an N-methylcarboxamido group reduces 
the activity by 25-2000 fold. Replacement by acetoxymethyl or hydroxymetbyl groups 
decreases the activity by factors ranging from two to five. It appears that a variety of 
ester groups can be accomodated without substantially changing the compound's activity. 
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These initial results suggested the presence of at least one and possibly two H -bond 
acceptor sites localized in the vicinity of the two oxygens in the 2-beta-carbomethoxy 
group (Fig. 27). However, this' premise has been challenged by Kozikowski and co-
workers(44,45), who in recent years have synthesized and evaluated various cocaine 
analogs modified at C-2. Specifically, the carboxymethyl group was replaced with 
various moieties that are incapable of strong hydrogen-bonding. These groups include 
substituted isoxazoles and isoxazolines (44), and vinylic analogues of cocaine (45), as 
well as similar structural analogues of the 3-beta-para-chlorophenyl WIN compound 
(44,45). Analogues of the WIN-type compound were also synthesized in which the C-2 
vinylic group was hydrogenated to remove the pi electrons (46). 
These were then evaluated for their ability to block [3H]DA reuptake and 
pH]mazindol binding. The results of each of the studies indicated a lack of specific 
hydrogen-bond donor groups within the region of the cocaine (I) recognition site which 
surrounds the C-2 ester group and the probability of a different binding modality being 
available for the alkyl or alkenyl analogues versus their C-2 ester counterparts (46). 
3)The stereochemistry at the C-2 center has a significant impact on activity. 
Specifically, epimerization from the beta to the alpha configuration results in a decrease 
in activity by factors ranging from 30-200. This effect is not seen to this extent in 
compounds with a C-3-beta-hydroxyl or C-3-alpha-substituents (24). 
4) Substitution at the nitrogen can have a fairly significant effect on the activity as 
well. Replacement of the N-methyl with an allyl or benzyl reduced activity by a factor 
of seven or less. Replacement by an acetyl to form an amide or addition of a methyl 
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group to create quaternary salt decreased activity by factors of 33 and 11, respectively. 
The above initial evidence suggested that a reduction in the electron density of the 
nitrogen was detrimental to activity. However, in a recent study, N-sulfonylated analogs 
were synthesized, evaluated, and found to have activity comparable to or more potent 
than cocaine (I) in mazindol-binding and DA uptake experiments(48). Specifically, a 
trifluoromethanesulfonyI group ,one of the strongest electron withdrawing groups 
available (47), was substituted for the N-methyl thereby making the nitrogen electrons 
unavailable for protonation. This analogue had a potency equal to cocaine (I) while a 
sulfonylisocyanate derivative was two-fold more potent (48). 
The suggestion that a basic nitrogen is necessary for binding to the cocaine (I) 
recognition site would seem to be logical since at physiological pH, the nitrogen is 
protonated and would be attracted by the negatively charged carboxylate (51) at the 
aspartate-79 residue of the transporter molecule. However, the data above would tend 
to indicate that a neutral nitrogen bridge can provide high-affinity ligands and that a basic 
nitrogen is not an absolute requirement for binding (48). Ionic bond type drug-receptor 
interactions have a bond strength estimated to be eight to ten Kcal/mol (50), and since 
these sulfonamide derivatives cannot participate in this type interaction, they would be 
expected to have a much lower potency in comparison to cocaine (I). The binding of 
these analogues is more likely to be due to hydrogen-bonding or weak polar interactions. 
This is supported by the fact that those compounds exhibiting the possibility of additional 
interactions of these types show even higher affinity. The residue of the transporter that 
is the recognition site of the cocaine nitrogen may be one which can be either a 
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hydrogen-bond donor or acceptor such as an OH group on a tyrosine (48). This 
hypothesis would at least partially explain the report that the N-nitro derivative was found 
to be 13 times more potent that the N-nitroso (49), the former having one additional H-
bond acceptor site than the latter. Since the Asp-79 has been found to be necessary for 
DA uptake, it may be possible that the recognition site for cocaine and DA may overlap, 
but are not comprised of the exact amino acids (48). 
SPECIFIC AIMS 
The overall goals of this project are the following: 
1. Synthesis and structural elucidation of a series of cocaine analogs by alkylation and 
acylation of the amine nitrogen on position eight of the tropane ring. The specific 
compounds to be developed are the ethyl, n-propyl, isopropyl, n-butyl, benzyl, acetyl, 
propionyl, butyryl, and benzoyl derivatives. 
2. Biological evaluation of these cocaine analogs on ligand binding and dopamine 
uptake. 
3. Synthesis and structural elucidation of a series of 3-beta esters of ecgonine and their 
amide isosteres. 
4. Synthesis and structural elucidation of a small series of compounds in which the 3-
carboxylic acid moiety of benzoylecgoinine is reduced to a primary alcohol and esterified 
with various NSAIDs. These compounds are potential prodrugs for both the esterified 
NSAID and for benzoylecgonine. 
EXPERIMENTAL METHODS AND RESULTS 
SUPPLIES AND EQUIPMENT 
Chemicals 
Sodium Chloride 99+ % ACS, Sodium Carbonate granular 99.5 + % ACS, Sodium 
Hydroxide pellets 97 + % ACS, Potassium Hydroxide pellets 85 + % ACS, Sodium 
Sulfate 99% ACS, Methyltrifluoromethane-sulfonate 99+%, l-Chloroethyl 
Chloroformate, 98 %, Nitromethane 95 + %, Propionic Acid 99 + %, 1 1'-, 
Carbonyldiimidazole, Acetylsalicyloyl Chloride 95%, Acetylsalicylic Acid +99%, 
Butyric Acid 99+%, Benzonitrile, Calcium Hydride 90-95%, Acetone 99.5%, Acetyl 
Chloride 99+ %, Benzaldehyde 99+ % ,Sodium Cyanoborohydride 95%, Butyryl 
Chloride, Borane-Tetrahydrofuran Complex, Aldrich Chemical Company Inc., 
Milwaukee, WI, Potassium Permanganate ACS, Butyric Anhydride 99%,Charcoal 
Activated, Salicylic Acid, Tetramethylsilane 99.9 %, Acetic Anhydride, Indomethacin, 
Ibuprofen, Postassium Carbonate Anhydrous ACS, Propionic Anhydride, Sigma 
Chemical Company, St. Louis, MO, Ethyl Acetate GC, HPLC, Acetone, Tech Grade, 
Baxter Healthcare Corporated, Muskegon, MI, Ethyl Ether Anhydrous, AR, Sodium 
Bicarbonate, Chloroform AR, Methyl Alcohol Chromar HPLC, Methylecgonine HCI, 
Cocaine HCL, Mallinckrodt, Paris, KY, Hexane 97% n-hexane (HPLC), Ammonium 
Hydroxide 30%, Instra-analyzed reagent, Trace Metal Analysis, J.T. Baker, 
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Phillipsburg, NJ, Acetonitrile UV, HPLC, GC, Baxter Burdick and Jackson, McGraw 
Park, IL 
Sulfuric Acid ACS, Hydrochloric Acid ACS, Acetic Acid Glacial Acetic Acid,Toluene 
ACS, 1,4-Dioxone ACS, Darco 6-60 Activated Carbon, Acetic Anhydride ACE, Fisher 
Scientific, Fairlawn, NJ 
Glassware 
All reactions unless otherwise noted were carried out in Kimax glassware. The types and 
volumes are listed in each reaction procedure. 
Equipment 
A Yamato HiTech Rotary Evaporator Model RE-51 , Yamato water bath Model HT-51 , 
and Gast Vacuum Pump Model No. 0523-U4B-6180DX were used for reduced pressure 
evaporations. Melting points were obtained on a Thomas Hoover Capillary Melting 
Point Apparatus and are uncorrected. Corning Hot Plate/Stirrers were used to maintain 
constant stirring and/or temperature during the reactions. Solid probe GeMS analyses 
were performed on a Finnigan Model 9610 gas chromatograph-4000 Series mass 
spectrometer. Other GCMS analyses were conducted on a Finnigan MAT5100 series gas 
chromatograph-mass spectrometer. FT-IR analyses were performed on a Mattson Polaris 
IR fitted with an HP 7470A plotter. Samples were dissolved in chloroform, placed on 
the NaCI plates, and allowed to evaporate. Elemental analyses were performed by 
Atlantic Microlab P.O. Box 2288, Norcross, GA, 30091, for C, H, and N composition. 
Nuclear Magnetic Resonance Analyses were performed on either a Varian Gemini 300 
(300 MHz) or a Varian VXR-400 (400 MHz) NMR with conventional quadrature. 
Chemical shifts are reported in {, ppm downfield from and internal tetramethylsilane 
(TMS) standard or in relation to residual CHCI3• 
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SYNTHETIC PR0CEDURES 






























Procedure 1. Methylecgonine (II)(ME) (1.00 g, 5.0 mmol) was suspended in a 
mixture of acetonitrile (ACN) (40.0 mL) and pyridine (1.0 mL), contained in a 100 mL 
round-bottomed flask fitted with a relux condenser column and a magnetic stirrer. The 
mixture was cooled to 0 °C and the appropriate anhydride (7.0 mmol) was added 
dropwise over 6 to 10 min. The reaction mixture was refluxed for 48 hr, and allowed 
to come to room temperature. Water (60 mL) was added and the volume of solution was 
evaporated to 10% of the original volume under reduced pressure to remove the pyridine. 
A solution of sodium bicarbonate (10%) was added to the resulting residue with swirling 
until the mixture was basic to litmus. This alkaline mixture was extracted five times with 
(5 x 10 mL) of ether. The organic layers were combined and evaporated to 25% of the 
original volume under reduced pressure and then allowed to evaporate completely in the 
hood overnight. A total of five attempts were made using both butyric anhydride and 
acetic anhydride. 
Procedure 2. Nitromethane (CH3N02) (10 mL) and triethylamine (0.4 mL), ME 
(11)(100 mg, 0.5 mmol) , was dissolved in a 50 mL Erlenmeyer flask fitted with a 
magnetic stirrer. The appropriate anhydride (1.2 mmol) was added dropwise over 6 to 
10 min with continuous stirring. The reaction mixture was allowed to remain at room 
temperature under nitrogen for 24 hr, water (15 mL) was added and the volume reduced 
to 10% of the original by under reduced pressure. Sodium bicarbonate (10 %) was added 
to the remaining solution until it became basic to litmus and then this aqueous mixture 
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was extracted three times with (3 x5 mL) of ether. The organic extracts were combined 
and washed with brine. The organic layer was dried over anhydrous Na2S04 , filtered, 
and the filtrate allowed to evaporate from an open container in the hood. Two reaction 
attempts were made with both acetic anhydride and butyric anhydride. 
Acid Chlorides 
Methylecgonine Hel (490 mg, 2.09 mmol) was added to 40 mL ethyl acetate 
contained in a 100 mL round-bottomed flask fitted with a reflux condenser and magnetic 
stirrer. Pyridine (4.0 mL) was then added. The appropriate acid chloride (2.6 mmol) 
was dissolved in 4 mL of ethyl acetate and added dropwise over 10 min with continuous 
stirring. The reaction mixture was heated to 70°C for 24 hr, allowed to come to room 
temperature and filtered. The solvent was removed under reduced pressure and 
approximately 20 mL ether added to the residue. The organic layer was extracted three 
times with (3 x20 mL) of distilled water. The ether layer was then allowed to evaporate 
from an open container in the hood. A total of seven reactions were attempted utilizing 
acetylsalicyloyl chloride (3), salicyloyl chloride (2), and butyryl chloride (2). 
For each of the above procedures, specific products present in the reaction 
mixture were identified via GC/MS. However, none could be isolated in quantities 
sufficient for analytical characterization or yield determination. 
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Methyl trifluromethanesulfonate (CH30Tt) (1.13 mL, 10 mmol) was added 
dropwise to a cooled solution (ice water bath) of carbonyldiimidazole (CBMI) (810 mg, 
5 mmol) in 10 mL of redistilled nitromethane (CH3N02) contained in a 50 mL 
Erlenmeyer flask fitted with a magnetic stirrer. This solution was added dropwise over 
6 to 10 min to a suspension of the appropriate acid (5 mmol) in 10 mL of CH3N02 
contained in a 50 mL round bottomed flask fitted with a reflux condenser column and a 
magnetic stirrer. After 5 min, ME (11)(400 mg, 2 mmol) was added. The reaction 
mixture was refluxed under nitrogen for 80 hr, and allowed to come to room 
temperature. The reaction was quenched with 5 mL water and extracted into 15 mL of 
ether. The ether extract was washed twice with (2x20 mL) of saturated NaHC03 and 
twice with (2 x20 mL) of brine. The organic layer was dried over anhydrous Na2S04 , 
filtered, and each solution of crude esters were allowed to evaporate to dryness under the 
hood. 
Each product was analyzed USIng GC/MS. The GC/MS spectra indicated the 
presence of the acetate (lla), propionate (11c) and butyrate (lId) esters. Not enough of 
the acetate (11a) nor butyrate (lId) esters could be isolated for analysis, and these crude 
mixtures were used in an attempt to make the 2-carboxylic acid derivatives. Using 
preparative thin layer chromatography (PTLC), only the propionic acid ester (11c) of ME 
was isolated and only in a quantity sufficient to perform GC/MS analysis. In each 
reaction, the remaining material was unreacted ME (II). 
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ANALYTICAL: 
[lR-( exo, exo) ]-3-propionyloxy-8-ethyl-8-azabicyclo[3.2.1 ]octane-2-carboxylic acid, 
methyl ester (IIc): GC/MS m/z 255 (M+,12.33), 198 (6.85),182 (60.27),94 (41.10), 
82 (100), 57 (17.81). 
In the reactions using salicylic and acetylsalicylic acids, the GC/MS revealed a 
complex mixture of products including minute amounts of each of the desired esters. 
The GC/MS analysis indicated that none of the mixtures contained enough of the desired 
products to allow isolation and structural characterization. 
Attempted Hydrolysis of the 2-Methyl Ester Products to Yield the 2-Carboxy-3B-
Esters (See Scheme 2) 
The crude ester mixtures produced in the above synthetic reactions were 
suspended in water in a 100 mL round-bottomed flask fitted with a reflux condenser and 
magnetic stirrer. The reaction was refluxed for 4 to 5 hr and allowed to come to room 
temperature. The aqueous solution was extracted 3 times with (3 x30 mL) portions of 
ether, and the aqueous portion was evaporated to near dryness under reduced pressure. 
The flask was stoppered and placed in the refrigerator overnight. No crystals formed. 
The solution was evaporated to dryness under reduced pressure. Absolute alcohol was 
added and the solvent was removed under reduced pressure. For each reaction, GC/MS 
indicated the presence of ecgonine (IV) and ecgonidine as well as small amounts of the 
desired free acid. Only the butyric acid ester (IVd) was isolated in any quantity 




(IVd): GC/MS mlz 254 (M + ,6.80), 168 (74.8), 124 (100), 108 (5.44), 87 (25.85) 
N-MODIFIED COMPOUNDS 











Benzoylecgonine (III)(BE) (1.53 g, 5.3 mmol) was dissolved in 140 mL water and 69 mL 
acetonitrile contained in a 500 mL round-bottomed three neck flask fitted with a pH 
meter and magnetic stirrer. Potassium permanganate (1.35 g, 8.54 mmol) dissolved in 
52 mL water was added dropwise over 10 hr. The pH was kept slightly acidic by 
addition of a solution of 40% acetic acid (HOAc). The reaction was allowed to stir 
overnight at room temperature. Methanol (MEOH) (10 mL) was added and the solution 
stirred for 1 hr. Activated charcoal and celite were added and the mixture stirred for 30 
min and then vacuum filtered. This procedure was repeated until the filtrate was 
colorless. The filtrate was then treated with Hel (56 mEq) and evaporated to dryness 
under reduced pressure. The residue was stored in vacuo over KOH overnight. The 
residue was dissolved in absolute alcohol, heated to boiling and filtered. The filtrate was 
concentrated by evaporation under reduced pressure and placed in the refrigerator. No 
precipitate formed. The remaining solvent was evaporated under reduced pressure and 
an IH NMR performed. The IH NMR spectrum indicated that the material isolated was 
BE (III). 
Meltzer's Method Modified (See Scheme 4) 
Cocaine (1)(5.00 g, 16 mmol) suspended in o:-chlorethyl chloroformate (ACE-Cl) 
(15 mL) was placed in a 50 mL round-bottomed flask fitted with a reflux condenser and 
magnetic stirrer. The flask was placed in an oil bath, heated to 110-115°C, and refluxed 
under N2 for 24 hr. The reaction was allowed to come to room temperature and the 
solution was evaporated to dryness under reduced pressure. The residue was dissolved 
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in a minimum of CH2CI2, and cold 2N HCl added until the reaction mixture was acidic 
to litmus. This acidic mixture was extracted twice with (2 x 15 mL) of water to remove 
the unreacted cocaine HCI. The organic component was evaporated to dryness under 
reduced pressure, a minimum of MEOH added and heated to 60°C overnight. The 
reaction was then allowed to come to room temperature and was evaporated to dryness 
under reduced pressure. The residue was dissolved in a minimum of CH2Cl2 and washed 
with saturated NaHC03 • The organic layer was dried over anhydrous Na2S04, filtered 
and evaporated to dryness under reduced pressure. The product was found to be 
analytically pure norcocaine (V)(NC) by GC/MS. The product was an amber oil 
weighing 4.60 g (96% yield) 
ANALYTICAL: 
Norcocaine (V): oil 96% yield; GC/MS m/z 289 (M + ,9.59), 184 (28.77), 168 
(21.90), 152 (2.70), 105 (100), 77(78.08), 59 (12.33) ; FT-IR cm-1 2934, 2952 (ring 
CH2), 1733,1717 (carboxyls), 1456 (aromatic), 1274 (2 ° amine), 715 (NH 2 ° aC); IH 
NMR (300 MHz, CDCI3) 0 2.5 (m, 1H,C4-H), 3.0 (m, 1H,C2-H), 3.4 (m,2H,C5-H,C1-H), 
3.6 (s,3H,OCH3)' 5.0 (m,IH,C3-H), 7.2-8.0 (m,5H,Ar-H). 























Norcocaine (V)(NC) (2.01 g, 6.9 mmol) was dissolved in MEOH (40 mL) in a 100 
mL flask fitted with a magnetic stirrer and rubber septum. The appropriate aldehyde or 
ketone (8.1 mmol) was added with a syringe under N2 over 6 to 10 min. Sodium 
cyanoborohydride (NaCNBH3) (0.240 g, 3.82 mmol) was dissolved in a minimum of 
MEOH and added with a syringe to the reaction mixture. The reaction was allowed to 
stir at room temperature for 18 hr. The solution was made acidic to litmus with IN HCI 
and extracted 3 times with (3 x40 mL) ether and the ether extracts were discarded. The 
aqueous layer was made basic to litmus using a solution of 5% NaHC03 and extracted 
3 times with (3 x40 mL) ether. The organic extracts from the second extraction process 
were combined and dried over anhydrous Na2S04, filtered, and the solvent removed 
under reduced pressure. Each tertiary amine product was recrystallized from hexane. 
Acetaldehyde, propanaldehyde, butyraldehyde and benzaldehyde were used in the 
above procedure. The ketone used was acetone. 
ANALYTICAL: 
[lR-(exo, exo )]-3-benzoyloxy-8-ethyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid, 
methyl ester (Va): MP 135°C, 28% yield (hexane); GC/MS m/z 289 (5.56), 258 
(2.42), 184 (20.92), 152 (2.07), 108 (9.53), 105 (100), 77 (76.67); FT-IR cm-1 2954 
(ring CH2), 1740, 1734 (carbonyl), 1601 (aromatics), 1457 (alkyl), 1437 (CH2-N), 1234 
(COOCH3), 668 (aromatics); lH NMR (300 MHz, CDCI3) 0 1.0 (t,3H,N-CH2-CH3), 2.3 
(q,2H,N-CH2)' 2.6 (m,lH,C4-H), 3.1 (m,lH,C2-H), 3.3 (m,2H,C5-H,C1-H), 3.5 
60 
(s,3H,OCH3)' 5.2 (m,lH,C3-H), 7.1-8.1 (m,5H,Ar-H); Elemental Analysis Calcd. for 
C18H23N04: C, 66.25; H, 6.65; N, 4.81. Found: C,66.25; H,6.68; N, 4.79. 
[IR -( exo, exo) ]-3-benzoyloxy-8-propyl-8-azabicyclo[3.2.1 ]octane-2-carboxylic acid, 
methyl ester (Vb): MP 135°C, 33% yield (hexane ); GC/MS mlz 288 (4.74), 184 
(21.00), 168 (11.90), 136 (6.21), 122 (1.25), 105 (100), 77 (79.96), 59 (21.73); FT-IR 
cm-1 2955, 2921 (ring CH2), 1734, 1718 (carbonyl), 1616, 1601 (aromatic), 1457(alkyl), 
1447(OCH3), 1437(N-CH2); IH NMR (300 MHz, CDCI3) 0 1.0 (t,3H,N-CH2-CH2-CH3), 
1.8 (m,2H,-CH2)' 2.3 (q,2H,N-CH2)' 2.6 (m,lH,C4-H), 3.0 (m,lH,C2-H), 3.3 
(m,2H,C5-H,C1-H), 3.5 (s,3H,OCH3) , 5.1 (m,lH,C3-H), 7.1-8.1 (m,5H,Ar-H); 
Elemental Analysis Calcd. for C19H25N04: C, 66.88; H, 7.53; N,4.21. Found: 
C,68.86; H,7.50; N, 4.20. 
[IR-(exo, exo)]-3-benzoyloxy-8-isopropyl-8-azabicyclo[3.2.1]octane-2-carboxyliGlcid, 
methyl ester (Vc): MP 130°C, 31 % yield (hexane); GC/MS m/z 331 (M+, 7.64), 300 
(4.33),226 (9.73),210, (49.34), 122 (23.51), 105 (86.75),77 (100), 59 (12.05); FT-IR 
cm-1 2955,2921 (ring CH2), 1734, 1718 (carbonyl), 1616, 1601 (aromatic), 1457 (alkyl), 
1447 (OCH3), 1437 (CH2-N); IH NMR (300 MHz,CDCI3) 0 0.8-1.0 (s,6H,N-CH2-
(CH3)2)' 2.2 (m, 1H,N-CH), 2.6 (m, 1H,C4-H), 3.0 (m, 1H,C2-H), 3.3 (m,2H,C5-H,C1-H), 
3.6 (s,3H,OCH3)' 5.2 (m,lH,C3_H), 7.4-8.0 (m,5H,Ar-H); Elemental Analysis Calcd. 
for C19H25N04: C, 68.88; H, 7.53; N, 4.21. Found: C,68.85; H, 7.50; N, 4.20. 
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[lR-( exo, exo )-3-benzoyloxy-8-(n-butyl)-8-azabicyclo[3 .2.1]octane-2-carboxylic acid, 
methyl ester (Vd): oil, 37% yield (hexane); GC/MS m/z 345 (M+, 6.85), 314 (3.14), 
240 (9.97), 224 (55.11), 136 (23.15), 124 (10.32), 105 (100), 77 (95.51), 57 (20.59); 
FT-IR cm· l 2955, 2921 (ring CH2), 1734, 1718 (carbonyl), 1616, 1601 (aromatic), 1457 
(alkyl), 1447 (OCH3), 1437 (CH2-N); IH NMR(300 MHz,CDC13) {) 0.9 (t,3H,N-CH2-
CH2-CH2-CH3), 1.7 (m,2H,N-CH2-CH2-CH2-)' 2.2 (m,2H,N-CH2-CH2-CH2),2.6 
(m,lH,C4-H), 3.0 (m,lH,C2-H), 3.3 (m,2H,Cs-H,C l -H), 3.6 (s,3H,OCH3)' 5.1 
(m,lH,C3.H), 7.2-8.1 (m,5H,Ar-H); Elemental Analysis Calcd. for C19H2SN04: 
C,69.56; H,7.82; N,4.05. Found: C,68.87; H,7.83; N, 4.26. 
[lR -(exo, exo )-3-benzoyloxy -8-benzyl-8-azabicyclo [3.2.1] octane-2-carboxylic acid, 
methyl ester (Ve): MP 96°C, 25% yield (hexane); GC/MS m/z 379 (M+, 3.51), 348 
(1.06), 258 (16.53), 170 (4.49), 105 (20.27), 91 (100), 77 (19.71); FT-IR cm-1 1750, 
1717 (carbonyl), 1278 (C-N), 1115 (C-O), 1034 (C-N), 714 (aromatic); IH NMR (300 
MHz,CDC13) {) 1.3 (s,2H,N-CH2-)' 2.6 (m,lH,C4-H), 3.0 (m,lH,C2-H), 3.2 (m,2H,Cs-
H,C1-H), 3.6 (s,3H,OCH3), 5.1 (m,lH,C3_H), 7.2-8.1 (m,5H,Ar-H); ElementalAnalysis 
Calcd. for C23H20N04: C, 72.82; H, 6.59; N, 3.69. Found: C, 72.66; H, 6.72; N, 
3.65. 

















Norcocaine (V)(898 mg, 3 nunol) was dissolved in a minimum amount of CH2Cl2 
contained in a 50 mL Erlenmeyer flask. Triethylamine (1.5 mL) was added and the flask 
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was fitted 'with a rubber septum and magnetic stirrer. The solution was cooled to 0 °c, 
and the appropriate acid chloride (4.23 mmol) added via syringe over 6 to 10 min. The 
reaction mixture was allowed to stir at O°C under N2 for 4 hr. The mixture was then 
allowed to come to room temperature and stir for 48 hr. The mixture was washed with 
10 mL of 2N Hel and again with 10 mL of distilled water. The organic layer was dried 
over anhydrous Na2S04, filtered and evaporated to dryness under reduced pressure. The 
products were recrystallized from hot hexane. The acid chlorides utilized in this reaction 
procedure were acetyl chloride, propionyl chloride, butyryl chloride and benzoyl 
chloride. 
ANALYTICAL: 
[lR-( exo, exo) ]-3-benzoyloxy-8-acetyl .. S-azabicyclo[3 .2.1 ]octane-2-carboxylic acid, 
methyl ester (Vi): MP 138°C, 32% yield (hexane); GC/MS m/z 331 (M+, 4.11), 
288 (4.11),225 (4.11),210 (16.10),194 (8.23),168 (17.78),136 (5.97),105 (79.45), 
77 (100), 59 (7.48); FT -IR cm-1 1740, 1734 (ester carboxyls), 1672 (amide I, 3 ° 
amide), 1616,1601 (aromatic), 1234 (methyl ester), 1223 (amide II), 1204 (C-N); IH 
NMR(300 MHz,CDCI3) 0 1.9 (s,3H,COCH3), 2.3 (m,IH,C4-H), 3.0 (m,IH,C2-H), 3.7 
(s,3H,OCH3)' 4.1 (m,2H,Cs-H,C1-H), 5.3 (m,IH,C3_H), 7.2-7.5 (m,5H,Ar-H); 
Elemental Analysis Calcd. for ClsH21NOs: C, 65.25; H, 6.34; N, 4.22. Found C, 
65.63; H, 6.59; N, 4.73. 
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[lR-( exo, exo) ]-3-benzoyloxy-8-propionyl-8-azabicyclo[3 .2.1 ]octane-2-carboxyliacid, 
methyl ester (Vg): oil 39% yield; GC/MS m/z 288 (1.05), 212 (1.47), 168 (17.79), 136 
(8.57), 105 (100),77 (41.27); FT-IR cm-1 1740, 1734 (ester carboxyls), 1672 (amide I, 
3 0 amide), 1616,1601 (aromatic), 1234 (methyl ester), 1223 (amide II), 1204 (C-N); IH 
NMR(300 MHz,CDCI3) {) 1.7 (t,3H,-CH3)' 1.9 (q,2H,-COCH2-)' 2.3 (m,lH,C4-H), 3.0 
(m,lH,C2-H), 3.7 (s,3H,OCH3), 4.2 (m,2H,Cs-H,CcH), 5.3 (m,lH,C3_H), 7.2-7.5 
(m,5H,Ar-H); Elemental Analysis Calcd. for C19H23NOs: C, 66.08; H, 6.66; N, 4.06. 
Found: C, 66.26; H, 6.66; N, 4.71. 
[lR-( exo, exo) ]-3-benzoyloxy-8-butyryl-8-azabicyclo[3 .2.1 ]octane-2-carboxylic acid, 
methyl ester (Vh): oil 31 % yield; GC/MS m/z 359 (M+, 1.37), 329 (1.37), 253 
(1.37), 179 (1.37), 135 (13.70), 107 (12.33),105 (100),77 (58.36),59 (4.11); FT-IR 
cm-1 1740, 1733 (ester carboxyls), 1671 (amide I, 30 amide), 1616, 1600 (aromatic), 
1234 (methyl ester), 1223 (amide II), 1204 (C-N); IH NMR(300 MHz,CDCI3) {) 1.7 
(t,3H,-CH3)' 1.8 (m,2H,-CO-CH2-CH2)' 1.9 (q,2H,-COCH2-)' 2.3 (m,lH,C4-H), 3.0 
(m,lH,C2-H), 3.7 (s,3H,OCH3)' 4.1 (m,2H,Cs-H,C 1-H), 5.3 (m,lH,C3_H), 7.2-7.5 
(m,5H,Ar-H); Elemental Analysis Calcd. for C19H23NOs: C, 66.85; H, 6.96;N, 3.89. 
Found: C, 66.65; H, 6.99; N,3.81. 
[IR-(exo, exo) ]-3-benzoyloxy-8-benzoyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid, 
methyl ester (Vi): oil 27% yield; GC/MS m/z 289 (15.07), 272 (4.11), 184 (36.99), 
168 (17.81), 152 (2.74), 136 (6.85), 105 (100), 77 (68.49), 59 (12.33); FT-IR cm-1 
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1740, 1734 (ester carbonyls), 1672 (amide I, 3 0 amide), 1616, 1601 (aromatic), 1234 
(methyl ester), 1223 (amide II), 1204 (C-N); IH NMR(300 MHz,CDCI3) 02.0 (s,2H,-
COCH2-), 2.3 (m,1H,C4-H), 3.3 (m,1H,C2-H), 3.7 (s,3H,OCH3)' 5.3 (m,1H,C3_H), 5.5 
(m,2H,Cs-H,C1-H), 7.2-8.0 (m,10H,Ar-H); Elemental Analysis Calcd. for C23H23NOs: 
C, 70.23; H, 5.85; N, 3.56. Found: C, 70.30; H, 5.95; N, 3.53. 














Methylecgonine (11)(2.00 g, 10 mmol) was suspended in 50 mL of the appropriate 
nitrile in a 100 mL Erleymeyer flask with warming and stirring. The solution was 
cooled to 0 °C and concentrated H2S04 (6 mL) added dropwise over 15 min. The 
reaction was warmed to room temperature and allowed to stir overnight under N2 . A 
solution of freshly prepared 10% KOH was added in 10 mL increments and the pH 
monitored with litmus until it reached 12.0. The solution was poured over 300 g ice. 
A precipitate formed upon stirring which was later identified as an inorganic compound, 
possibly KHS04 • The solution was filtered and the precipitate placed under vacuum. 
The filtrate was evaporated to dryness under reduced pressure and ether added to the 
residue. A precipitate formed and the solution was filtered, and this precipitate dried 
under vacuum. The solution was dried over anhydrous Na2S04, filtered and evaporated 
to dryness under the hood. GC/MS was performed on the residue and filtrates. No 
product formation was indicated, and the second filtrate proved to be ME (II). 
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BENZOYLECGONINE DERIVATIVES 
Synthesis of 2B-Hydroxymethyl..:3B-benzoyloxytropane (BOH) (VI) 
o 
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Benzoylecgonine (111)(1.00 g, 3.5 mmol) was dissolved in a minimum amount 
of dry acetronitrile contained in a 50 mL Erlenmeyer flask fitted with a magnetic stirrer 
and rubber septum. The flask containing the mixture was placed in an ice bath at DoC 
under N2 and 1.0 M diborane in THF (12.5 mL) was added slowly over 6 to 10 min via 
syringe. The solution was stirred at DoC for 2 hr, then allowed to come to room 
temperature, and stirred overnight. Excess diborane was destroyed by careful addition 
of MEOH. The solution was concentrated by evaporation under reduced pressure, and 
the remaining solution made acidic to litmus by addition of 6N HCl. The solution was 
then evaporated to dryness under reduced pressure and allowed to cool to room 
temperature. The residue was dissolved in a minimum of CH2Cl2 and was made basic 
to litmus with 6N NH40H. The mixture was separated, the organic layer was dried over 
anhydrous Na2S04, filtered, and evaporated to dryness. GC/MS indicated that the oily 
residue was analytically pure product. The tan solid alcohol (934.8 mg, 98% yield) 
crystallized upon standing in a drying cabinet. 
ANALYTICAL: 
2fj-Hydroxymethyl-3fj-benzoyloxytropane (VI): MP 85°C (no literature MP reported) 
98% yield (hexane); GC/MS m/z 275 (M+, 12.33), 170 (6.85), 154 (100), 105 (32.88), 
94 (34.25), 77 (34.25). 
Since the compound had been previously synthesized and structurally elucidated, no 
further analytical procedures were done. 
Synthesis of the Esters of 2B-Hydroxymethyl-3B-benzoyloxytropane 
(See Scheme 7) 
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The reaction conditions were identical to those described in the attempt to 
synthesize ME esters using the carbonyldiimidazole procedure. The following quantities 
oOf reactants were used: 0.02 mL (0.18 mmol) CH30Tf, 30.8 mg (0.20 mmol) 
carbonyldiimadazole, 49.0 mg (0.18 mmol) BOH (VI), and 0.57 mmol ibuprofen, 
naproxen, or indomethacin. GC/MS performed after 2 hr indicated that all of the BOH 
(VI) had reacted. After allowing the reaction to run overnight, there was no change in 
the GC/MS. After working up the reaction as described with the carbonyldiimidazole 
procedure, solid probe GCMS showed results consistent with a single component sample 
corresponding to the expected product. Each of the products were oils. 
ANAL YTICAL: 
2-( 4-isobutylpbenyJ) propionic acid, (3-benzoyloxy-2-tropyl)metbyl ester (VIa): oil 
22 % yield; GC/MS m/z 463 (M +, 2.71), 258 (60.44), 161 (20.49), 136 (16.32), 118 
(14.11), 105 (43.46), 104 (4.24), 94 (29.98), 91 (15.49), 82 (100), 77 (23.48), 57 
(9.89); FT-IR cm-1 2955, 2921 (ring CH2), 1740, 1734 (ester carbonyls), 1616, 1601 
(aromatic), 1457 (alkyls), 668 (aromatic); IH NMR (300 MHz, CDCI3) 0 0.9 Cd, 6H, 
CH-(CH3)2), 1.5 (d, 3H, -CH3), 1.8 (m, 1H, CH2CH(CH3)2), 2.3 (s, 3H, N-CH3), 2.4 
(m, 2H, Ar-CH2), 2.5 (m, 1H, C4-H), 3.1 (m, 1H, C2-H), 3.3 (m, 2H, Cs-H, C1-H), 3.5 
(d, 2H, -CH20CO-), 3.6 (d, lH, COCH-), 5.2 (m, IH, C3-H), 7.8-8.1 (m, 9H, Ar-H). 
2-( 6-methoxy-naphthyl) propionic acid, (3-benzoyloxy-2-tropyl)methyl ester (VIb): 
oil 26 % yield; GC/MS m/z 487 (M +, 1.45), 258 (35.81),229 (26.20), 185 (100), 154 
(13.72), 153 (15.45),136 (15.96),126 (3.35), 105 (30.80), 94 (27.08),77 (15.10); FT-
IR cm-1 2955, 2920 (ring CH2), 1740, 1734 (ester carbonyls), 1617, 1601 (aromatics), 
1260 (ether); IH NMR (300 MHz, CDC13) 0 1.5 (d,3H, -CH3), 2.3 (s, 3H, N-CH3), 2.5 
(m, IH, C4-H), 3.1 (m, 1H, C2-H) , 3.3 (m, 2H, Cs-H, C1-H), 3.5 (d, 2H, -CH20CO), 
3.6 (d, IH, -COCH-), 3.7 (s,3H, OCH3) 7.8-8.1 (m, 11H, Ar-H). 
1-( 4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid (3-benzoyloxy-2-
tropyl)methyl ester (VIc): oi120% yield; GC/MS m/z 614 (M+, 0.38),356 (3.15), 
258 (29.60), 139 (100), 136 (11.31), 111 (24.01), 94 (15.13) FT-IR cm-1 3200 (indole 
N-H), 2955, 2920 (ring CH2), 1740, 1734 (ester carbonyls), 1670 (amide I) 1617, 1600 
(aromatics), 1260 (ether), 1220 (amide II); IH NMR (300 MHz, CDCl3) 0 2.1 (s, 3H,-
CH3), 2.3 (8, 3H, N-CH3), 2.5 (m, 1H, C4-H) , 3.1 (m, 1H, C2-H), 3.3 (m, 2H Cs-H, 
C1-H), 3.5 (d, 2H, CH20CO), 3.6 (s, 2H, COCH2), 3.7 (s,3H, OCH3), 7.8-8.1 (m, 13 
H, Ar-H). 
DISCUSSION OF SYNTHETIC RESULTS 
The original research plan proposed the synthesis of derivatives of ecgonine 
involving esterification of and amide formation at the three position, and alkylation and 
acylation of the eight position. These compounds were to be synthesized from ecgonine 
(IV)(EC), norecgonine (NEC), or methylecgonine(II) (ME). Therefore the initial 
reactions were attempted with these goals in mind. 
ESTERIFICATION 
The esterification of the 3-0H of ME (II) was the first series of reactions that was 
attempted. The initial difficulty encountered in the synthesis of the ester series was the 
neutralization of methylecgonine Hel (ME Hel) to produce the free base. This was 
necessary because a proton source in the reaction mixture would deactivate the acidic 
reactants such as the acid chlorides or anhydrides. Due to the relative insolubility of the 
free base (ME) (II) in organic solvents, the standard neutralization of tropane salts such 
as the neutralization of cocaine Hel with KOH was not entirely successful. Unlike 
cocaine (I), methylecgonine (II) does not readily precipitate from aqueous solution. 
Consequently, the recovery yield of the ME (II) free base was only 15-30% compared 
with 90-98% for cocaine (I). Although the yield was relatively low, GC/MS data 
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confirmed that the ME(II) obtained was analytically pure. This product was used as the 
starting material in attempts to synthesize ester and amide derivatives of ecgonine (IV). 
Attempts were made to synthesize a series of short chain aliphatic ac.id esters, as 
well as two salicylate esters of the 3-hydroxy group of ME (II). Acid anhydrides or acid 
chlorides were utilized as the acyl donor groups in the attempted esterifcations. In 
addition to its limited solubility, the requirement of an aprotic solvent posed another 
problem in the esterification of ME (II). Dry benzene (10) has been used in the 
esterification of ME (II) to cocaine (I) with either benzoyl chloride or benzoic anhydride. 
However, the ME (II) obtained from the above neutralization procedure proved insoluble 
in benzene even at high temperatures. Other solvents evaluated for ME (II) solubility 
included acetonitrile, hexane, dioxane, tetrahydrofuran, toluene, ethyl acetate, 
dimethylsulfoxide, dimethylformamide, nitromethane, chloroform, and methylene 
chloride. Of these, only nitromethane solubilized the ME (II) to any extent. 
Vogel (52) describes the use of acid chlorides and anhydrides as being an effective 
synthetic method for esters in which the alcohol of interest is either primary or 
secondary. The 3-beta-OH of ME (II) is secondary and several reactions were attempted 
with this scenario. Specifically, a total of seven attempts were made with butyric 
anhydride and acetic anhydride in two separate reaction procedures. Another seven 
reactions were run using either acetylsalycyloyl chloride (3), salicyloyl chloride (2), and 
butyry I chloride (2). 
In the first procedure utilizing the anhydrides, acetonitrile was used to suspend 
the ME (II), and pyridine was the agent used as a catalyst (kb = 1.4 X 10-9) for the reaction. 
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Once the reaction was removed from heat and cooled, water was added. The azeotropic 
mixture formed with the pyridine was then removed by evaporation under reduced 
pressure. Aqueous sodium bicarbonate was added to the residue to neutralize the free 
carboxylic acid. The presumed product was then extracted from this aqueous mixture 
into ether and the ether was allowed to evaporate under the hood. In the second 
procedure, nitromethane was utilized and the solvent and triethylamine (kb=5.65 x 10-5) 
as the catalyst. Thus both the solubility of the starting material and the strength of the 
catalyst were increased. The reaction was allowed to remain at room temperature under 
nitrogen. The subsequent work up was the same as that used in the first procedure, with 
additional drying of the organic extracts using anhydrous Na2S04• The GC/MS results 
indicated that in all of the reaction attempts, only minute amounts of the acetate ester 
formed in a quantity insufficient for further analytical evaluation. 
The procedure utilizing the acid chlorides was a standard esterification in which 
ethyl acetate was employed as the reaction medium and pyridine was utilized as the 
catalyst and to neutralize the hydrogen chloride formed during the reaction. The 
presence of minute quantities of each product were verified via GC/MS in each of the 
seven reactions attempted using acetylsalicyloyl chloride, salicyloyl chloride, or butyryl 
chloride; however, no product was present in a quantity sufficient for further analytical 
determination. 
As it became obvious that conventional methods of esterification would not be 
productive, a search for an effective approach was conducted. Paul and Anderson 
(53,54) reported that N, N' -carbony ldiimidazole was useful in peptide formation. Saha 
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(55) took this one step further with the bis-alkylation of carbonyldiimidazole by methyl 
triflate to form 1,1' -carbonyl-bis-(3-methylimidazolium)triflate (CBMIT). The use of this 
latter reagent virtually eliminated the problems associated with peptide and ester 
formation, such as racemization, complex reagents, or side-reactions. The highly 
reactive acyl imidazolium ion intermediate facilitates the reaction. It readily donates the 
acyl group to the peptide fragment, amino acid, or alcohol to yield peptides, amides, or 
esters. The best solvent found for this reaction is nitromethane. This eliminated the 
problem of solubility associated with ME (II). 
The products of each of these esterfication attempts were analyzed using GC/MS. 
For the reactions in which acetic, propionic and butyric acids were used, the spectrum 
indicated the formation of a very small amount of the desired product, and that the 
remaining material was unreacted ME (II). Using preparative thin layer chromatography, 
only the propionic acid ester of ME (IIc) was isolated and only in a quantity 
(approximately two mg) sufficient to perform GC/MS analysis proving that particular 
band was the propionic acid ester. In the reactions using salicylic and acetylsalicylic 
acids, the GC/MS revealed a complex mixture of products including small amounts of 
each of the desired esters, the free acids, the acetate ester of methylecgonine, and the 
starting material, ME (II). The GC/MS analysis indicated that none of the mixtures 
contained enough of the desired products to attempt separation. In the acetylsalicyloyl 
acid reaction, a transesterification of the 3-beta-OH of ME (II) by the highly reactive 
acetyl ester group in the acetylsalicylic acid competed with the desired esterification of 
that group with the carboxylic acid moiety on the salicylate. GC/MS evidence indicated 
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that the major product was the acetyl ester of ME (Ve) which fanned in a ratio of nearly 
10: lover the desired acetylsalicyloyl ester (Vk). Neither product formed in quantities 
sufficient for structural verification. 
Despite the utilization of activated acids, acid derivatives, or carbonyl transfer 
groups, the reactions in which the esterification of the 3-beta-OH was of interest were 
quite unreactive. The relative lack of solubility of t1!.e ME (II) alone could not account 
for these results. A molecular model evaluation of the ME (II) molecule revealed a high 
probability for hydrogen bonding between the 3-beta-OH hydrogen and the carbonyl 













reactivity of the hydroxyl group toward esterification by reducing the availability of the 
electrons of the oxygen for attack on the carbonyl carbon of the acyl species and would 
therefore explain why these reactions produced less than optimum results. 
In an attempt to synthesize and isolate any ecgonine derivative of any of the esters from 
the crude reaction mixtures, a procedure similar to that of Bell and Archer (56) for the 
synthesis of benzoylecgonine (III) from cocaine (I) was utilized. The reaction was 
followed by GC/MS to minimize the formation of ecgonine (IV) and ecgonidine which 
were undesired side products of the reaction. Of all these reaction attempts, only the 
butyrate ester (IVb) was formed in any isolatable quantity. 
N-DEMETHYLATION 
An initial search of the literature involving the N-demethylation of cocaine (I) or 
benzoylecgonine (III) revealed two major approaches. Findlay's (57) method utilizing 
potassium permanganate oxidation of benzoylecgonine (III) was a relatively facile 
procedure and produced an 82 % yield of norbenzoylecgonine HCI. Stenberg (58) 
described an improved method of preparing norcocaine (V) from cocaine (I) by 
controlling the pH while using the same type oxidation employed by Findlay. 
Maintaining an acidic pH was necessary to prevent the acyl transfer of O-acetyl and 0-
benzoyl groups to the 2° amine that occurs in basic media (59) in similar tropane 
systems. Since the N-modified ecgonine derivatives of these compounds were of interest, 
it was determined that attempting the reaction with benzoylecgonine (III), while 
controlling the pH, would enhance the yield, and eliminate an additional hydrolysis step. 
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In each of the ten reactions attempted, the IH NMR spectrum of the product 
contained the N-CH3 peak located at 0 2.2 ppm, and there was no evidence of the 
presence of the desired nor-methyl product. The remainder of the IH NMR spectrum 
was consistent with that of the starting material and there was no indication of a mixture 
of benzoylecgonine (III) and nor-benzoylecgonine. 
Baldwin (60) developed a reaction method by which direct demethylation of 
cocaine (I) was accomplished using chloroformate esters. He reported an 85 % yield of 
the norcocaine HCI when using 2,2,2,-trichloroethyl chloroformate and a 55% yield of 
the norcocaine (V) when vinyl chloroformate was employed. Borne (61), utilizing a 
similar reaction sequence with 2,2,2-trichloroethyl chloroformate, reported a yield of 
56% of the norcocaine HC!. However, both these methods were very time consuming 
and required several manipulations of the reaction mixture such as hydrolysis of the 
intermediate carbamate using zinc dust and several extraction procedures. With the 
expense of the starting material in mind, the search continued for a better approach. 
Meltzer and co-workers (62) utilized a-chloroethyl chloroformate (ACE-CI) in 
their N-demethylation reaction with impressive results (74% norcocaine (V» requiring 
a minimum of time and manipulation. The conditions for the hydrolysis of the carbamate 
intermediate were appropriate for use in the presence of such sensitive functional groups 
as the esters on the C-2 and C-3 positions of the tropane ring. However, in an effort to 
further improve the yield, this method was modified by separating the unreacted cocaine 
(I) from the intermediate carbamate via an extraction into acidic water prior to the 
hydrolysis of the carbamate with methanol. As a result, a 96% yield of the norcocaine 
78 
base (V) was obtained. The structural identity of the compound was confirmed by 
GC/MS, FT-IR, and IH NMR. The characteristic pattern of this tropane in the GC/MS 
included peaks at 59 (COOCH3), 77 (C6H5), 168 (l-methyl-l-pyrolinium ion), and 289 
(M +). The IH NMR confirmed the absence of the N-methyl peak in the area of {) 2.8 
ppm. The FT-IR confirmed the presence of the secondary amine (1275 cm-l). 
N-ALKYLATION 
Historically, alkylation of the tropane nitrogen (Scheme 8) has been accomplished 








N -cy lop ropy lmethy lnorcocaine, N -ally lnorcocaine, and N -dimethy lall y lnorcocaine . 
Millius (64) synthesized and characterized a series of N-substituted 3-(4-
flurophenyl)tropane derivatives. Abraham (65) also reported the synthesis of a group of 
N-modified cocaine derivatives, one of which was N-benzylnorcocaine. Although each 
of the procedures cited above varied in such parameters as the type of catalyst used, the 
reaction time, and/or the solvent system, all results were similar, and all required the use 
of flash chromatography for purification. Also the risk of quaternary ammonium salt 
formation was significant, creating further difficulties in separation and reduction of 
yield. To eliminate the necessity of column chromatography, the possibility of 
quatemization, and to maximize the yield, reductive alkylation was investigated. Vogel 
(66) describes the process by which a primary or secondary amine is reductively 
alkylated under catalytic conditions in an ethanol solution using hydrogen under pressure 
and Raney nickel. The use of sodium borohydride is also indicated as an effective in situ 
reducing agent when primary amines are mixed with aliphatic aldehydes or ketones. 
Further investigation (67,68) revealed the use of sodium cyanoborohydride as a selective 
reducing agent for a given functional group in the presence of other sensitive functional 
groups. This reagent appeared ideal for use with the cocaine (I) molecule with its 
susceptible ester groups. Another advantage of the sodium cyanoborohydride molecule 
lies in the strongly electron-withdrawing properties of the cyano group, creating a milder 
and more selective reducing agent than sodium borohydride (Fig. 32). By following the 
progress of the reactions to completion with GC/MS, the use of flash chromatography 
was eliminated and recrystallization was utilized for purification. The procedure utilized 
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for this series of reactions was a modification of a synthetic scheme originally described 
by Oka (69). 
The GC/MS spectrum contained the expected parent ion corresponding to the 
molecular ion (M +) of each product and/or fragmentation patterns typical of tropanes 
(59, COCH3; 77, C6H5; 168, 1-methyl-l-pyrolinium ion), the IH NMR spectra verified 
the appearances of the appropriate patterns for the respective N -substituents at the 
expected chemical shifts such as the quartet-triplet (0 2.3, 1.0 ppm) indicative of the N-
ethyl derivative (Va), the triplet-multiplet-triplet (0 2.3, 1.8, 1.0 ppm) of the N-propyl 
derivative (Vb), the multiplet-singlet (0 2.2, 0.8-1.0 ppm) of the N-isopropyl compound 
(Vc) , the triplet-multiplet-multiplet-triplet (0 2.2, 2.0, 1.7, 0.9 ppm) of the N-n-butyl 
compound (Vd); and, for the N-benzyl product (Ve) , the increased integration of the 
aromatic region (0 7.2-8.1 ppm) and the new singlet for the N-CH2 at {) 1.3 ppm. The 
FT-IR indicated the expected disappearance of the secondary amine band (1275 cm- I ) 
present in the starting material and expected absorbances characteristic of the functional 
groups in the desired products. Specifically, there was an increase in the aliphatic C-H 
bands. These products included N-ethylnorcocaine (Va), N-n-propylnorcocaine (Vb), N-
isopropylnorcocaine (Vc), N-n-butylnorcocaine (Vd), and N-benzylnorcocaine (Ve). 
N-ACYLATION 
The procedure used in this series of reactions was a standard amino-acylation 
reaction as discussed in March (71). A similar reaction sequence was reported by 
Abraham (65). The procedure is highly exothermic, and the temperature was controlled 
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with cooling to 0 °C. Triethylamine served to neutralize the Hel liberated by the 
reaction. 
The results for this series of reactions were similar to the N -akyl analogs. The 
products were characterized using GC/MS, FT-IR, IH NMR with support from elemental 
analysis. The GC/MS results indicated the expected parent ion and/or fragmentation 
pattern characteristic of these tropane derivatives (59, COCH3; 77, C6H5 ; 168, 1-methyl-
1-pyrolinium ion). The IH NMR data depicted the singlet (0 1.9 ppm) of the acetyl 
group of the N-acetyl derivative (Vi), the quartet-triplet (0 1.9, 1.7 ppm) of the N-
propionyl group of that derivative (Vg), the triplet-multiplet-triplet (0 1.9, 1.8, 1.7 ppm) 
of the N-butyryl group of that product (Vh); and the increased integration of the aromatic 
multiplet (0 7.2-8.0 ppm) and multiplet (0 2.0 ppm) of the benzoyloxy component of that 
product (Vi). [Each of the above characteristics of these spectra indicated the downfield 
shift expected in a comparison of a series of amines with the comparable amides]. In 
each instance, the FT-IR confirmed the presence of the amide I (1672 em-I) and II (1222 
em-I) bands, as well as the other functional groups expected. The products included N-
acetylnorcocaine (Vi), N-propionylnorcocaine (Vg), N-butyrylnorcocaine (Vh), and N-
benzoy lnorcocaine (Vi). 
AMIDE FORMATION 
The Ritter reaction (72) (Scheme 9) is a standard reaction utilized in the 
formation of amides from alcohols. This procedure appeared to be satisfactory for the 
purpose of synthesizing the 3(j-amide derivatives of ecgonine (IV). Secondary alcohols 
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will react with nitriles with the use of concentrated H2S04 and relatively polar solvents 
such as the nitrile of interest may be utilized. This would overcome the solubility 
concerns associated with ME (II). However, the hydrogen bond formation between the 
3fj-OH and the carbonyl oxygen of the 2fj-ester described in the discussion on ester 




R-OH + R'CN -~ .. RCNR' 
Ritter reaction 
Scheme 9 
BENZOYLECGONINE DER1V A TIVES 
Analysis of the product (EsteromGD) that is under clinical trials revealed the 
presence of BE (III) and related compounds. In addition to the proposed esterification 
of the 3-0H with selected NSAIDs, it was deemed feasible to couple the BE (III) 
molecule in a pro-drug fashion with these NSAIDs. Consequently, it was decided to 
combine the reduced BE (III) molecule via esterification with three commonly used 
NSAIDs: ibuprofen, naproxen, and indomethacin. The first step was to convert the 2-
carboxylic acid group of BE (III) into a primary alcohol. This primary alcohol could 
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then be esterified with the appropriate NSAID to yield a n double" prodrug, with the BE 
(III) moiety possessing the activity of the product in the clinical trials and the NSAID 
portion of the molecule having its anti-inflammatory activity. 
A procedure similar to the one reported by Lewin (74) was utilized in the 
synthesis of the starting material (BOH) (IlIa) of this series of compounds. The 
procedure utilizing carbonyldiirnidazole as an activated acyl carrier discussed in the 
section on attempted esterification was the reaction of choice in this situation as the 
molecules involved contained multiple reactive groups which increased the potential of 
complicated side reactions. The reactions were followed with GC/MS, which facilitated 
optimum product formation as evidenced by the disappearance of the starting material. 
Solid probe GC/MS was necessary to determine the presence and purity of the final 
products due to the lack of volatility of the compounds. In each case, the results were 




The Medications Development Division (MDD) of the National Institute of Drug 
Abuse (NIDA) has established a Cocaine Treatment Discovery Program (CTDP) to 
identify potential treatments for the medical management of cocaine abuse. This protocol 
is designed to identify compounds which either substitute for cocaine or antagonize 
cocaine's effects. The screening components of this program consist of initial in vitro 
biochemical assays of each compound. Compounds demonstrating appropriate in vitro 
activity then are utilized in in vivo pharmacological studies of mouse locomotor activity 
and rat drug discrimination and self-administration. Table 2 summarizes the procedure 
for each component of the CTDP screening. 
IN VITRO METHODS 
Each of the N-modified compounds were tested for their effects on radioligand 
(P25I]RTI-55) binding to and [3H]dopamine uptake by C6 cells expressing the eDNA for 




Cell Preparation: Cells were grown on 150 nun diameter tissue culture dishes. 
The medium was poured off the plate; the plate washed with 10 mL of phosphate 
buffered saline and 10 mL of lysis buffer (2 mM HEPES, 1 mM EDTA) was added. 
After 10 min, the cells were scraped from the plates, poured into centrifuge tubes and 
centrifuged for 20 min at 30,000 x g. The supernatant was removed, and the pellet was 
resuspended in 20 mL of 0.32 M sucrose with a Polytron at setting 7 for 10 sec. 
Assay: Each assay sample contained 50 ILL of the membrane (cell) preparation 
(approximately 50 ILg protein), 25 ILL of drug (from a solution of the drug dissolved in 
a minimum of MEOH) , and 25 JLL of [125I]RTI-55 (40-80 pMol) in a final volume of 250 
JLL. Krebes HEPES was used for all assays. Membranes were preincubated with the 
compounds of interest for 10 min prior to addition of [1251]RTI-55. The reaction was 
incubated for 90 min at room temperature in the dark and was terminated by filtration 
onto GP/C filters using a Tom-tech harvester. Scintillation fluid (50 JLL) was added to 
each square and the radioactivity remaining on the filter was determined using a Wallac 
tJ-plate reader. Competition experiments were conducted with duplicate determinations. 
The data was analyzed using GraphPAD Prism, which converted IC50 values to Ki values. 
[3Hl N eurotransmitter Uptake: 
Cell Preparation: The cell preparation procedure for the [1251-55] binding was 
utilized. 
Assay: For experiments involving uptake of PH]DA, the medium was removed 
and Krebs HEPES buffer (25 mM HEPES, 122 mM NaCI, 5 mM KCI, 1.2 mM MgS04 , 
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2.5 mM CaC12, 1 JLL pargyline, 0.2 g/100 mL glucose, 0.02 g/100 mL ascorbic acid, 
pH 7.4) was added. The uptake was initiated by the addition of PH]DA (20 mM, 
specific activity 20-53 Ci/mmol) in a final volume of 500 JLL. Mazindol (5 JLM) or 
imipramine (5 JLM) was used to define nonspecific uptake. Cells are preincubated for 
10 min with the compound of interest before the addition of the radioligand. Uptake was 
terminated after a 2 min incubation by removing the buffer. The plate was then placed 
on ice and washed twice with 1 mL phosphate-buffered saline that had been cooled in an 
ice bath. Trichloroacetic acid (TeA, 0.5 mL, 3%) was added to each well, the cells 
were allowed to sit for 15 min, and radioactivity in the TCA was determined by 















CTDP SCREENING AND PROFILING PROTOCOLS 
PROTOCOL 
Only compounds with a rational structural basis for interacting at the dopamine 
transporter will be tested for [12SI]RTI-55 binding activity, Human cloned dopamine 
transporter cell membranes (2001'1) are incubated in Krebs-HEPES buffer (2SmM 
HEPES, 120mM NaCI, SmM KCI, 2.5mM Cacl2, 1.2mM MgS04, Ip.M pargyline, 
2mg/ml glucose, and O.2mg/ml ascorbic acid) for 2 hours at 200C with 251'1 of test 
compound at 251'1 of [l25I]RTI-55 (0.05nM final concentration), Nonspecific binding 
is determined by incubating in the presence of 5p.M mazindol. Active compounds will 
then be tested for their ability to affect the rate of dopamine uptake in vitro, 
The initial behavioral screen consists of testing compounds alone and in combination 
with cocaine on locomotor activity in mice. This is accomplished through the use of 
an automated photocell monitor system. The effects of the test compound alone on 
locomotor activity is evaluated first. In this experiment, sufficient doses are tested in 
order to determine maximum effects and EDso values. For compounds which do not 
stimulate activity or are weak stimulant-type drugs (i.e. compounds which produce 
maximum stimulant effects less than cocaine), interaction studies will be conducted to 
determine the effect of the test compound on cocaine-induced locomotor activity. 
These compounds are tested for their ability to antagonize the stimulant effects of 
cocaine over an appropriate dose range. ADso values are calculated, when possible. 
The second tier test is drug discrimination. These experiments are conducted in 
standard 2-lever operant chambers. Depending on the results obtained from the 
locomotor activity studies, the test compound will either be tested for its ability to 
antagonize cocaine's discriminative stimulus effects or to generalize to the discriminat-
ive stimulus effects of cocaine. Drug discrimination antagonist studies are conducted 
when compounds demonstrate weak or no stimulant effects in locomotor activity 
studies. In this case, several doses of the test compound are tested in combination 
with the training dose of cocaine. drug discrimination substitution tests are conducted 
when compounds exhibit maximum stimulant effects which are equal to or greater than 
cocaine. For the substitution experiments, several doses of the test compound are 
tested for their ability to substitute for cocaine. Drug discrimination experiments are 
initially tested in rats. For those compounds which show a promising pharmacological 
profile, drug discrimination experiments in monkeys will be conducted. 
The third tier test is self-administration. These experiments are conducted in standard 
operant conditioning chambers. Antagonism of the reinforcing effects of cocaine is 
examined by assessing changes in rates of cocaine self-administration after pretreat-
ment with the test compound. Specificity of the effect is examined by comparing 
effects of the test compound on behavior maintained by cocaine and another reinforcer, 
At least two doses of the test compound shall be examined with two doses of cocaine. 
In selected cases, the ability of the test compound to maintain self-administration 
behavior is also assessed. Drug self-administration experiments are initially tested in 
rats. For those compounds which show a promising pharmacological profile, drug 
self-administration experiments in monkeys will be conducted. 
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RESULTS 
The results are summarized in Table 3 below. 
TABLE 3 
RESULTS OF BIOLOGICAL ASSAYS 
COMPOUND [125I]RTI-55 HILL [3H]DA UP- HILL 
BINDING Ki CO-EFFI- TAKE ICso CO-EFFI-
(oM) CIENT (oM) CIENT 
COCAINE(I) 351 +62 -0.98+0.08 240±2 -0.94+0.16 
Va 2259+331 -0.90±0.19 2007+981 -1.40+0.62 
Vb > 10/lM 
Vc > 10JLM 
Vd 494+53 -0.86+0.04 245+83 -0.63±0.03 
Ve 3925+501 -0.73+0.16 1216+264 -0.84+0.12 
Vf > 10jlM 
Vg > 10JLM 
Vh > 10JLM 
Vi 7136+1828 -0.91 +0.03 4645+1242 -1.32+0.36 
The results of the in vitro studies did not justify further investigation of the 
compounds, and no in vivo evaluations were performed. 
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DISCUSSION 
In the N-alkylated series of compounds, the N-ethyl, N-propyl, N-isopropyl, N-n-
butyl, and N-benzyl derivatives have lower affinities for ([l25I]RTI-55) radioligand 
binding to C6-hDAT cells than cocaine, the standard compound, for the same site. In 
the uptake assays, with the exception of the N-n-butyl derivative, each of these 
compounds was less potent than cocaine in blocking the uptake of pH]dopamine. The N-
n-butyl derivative was equipotent to cocaine in blocking the uptake of [3H]dopamine. 
All of the compounds in the N-acylated series including the N-acetyl, N-
propionyl, N-n-butyryl, and N-benzoyl derivatives have lower affinities for (P25I]RTI-55) 
radioligand binding to C6-hDAT cells than cocaine, the standard compound, for the same 




Esterification of the 3 .. beta-hydroxy of ME (II) proved to be infeasible using 
standard esterification techniques. Changes in the solvent, strength of the catalyst and 
the acylation agent (including the use of carbonyldiimidazole acyl activation) did not 
result in the formation of anything more than a negligible amount of any ester product 
as indicated from GC/MS analysis. No product could be isolated in a quantity that was 
adequate for comprehensive structural analysis. It is unlikely that the poor solubility of 
II alone could account for these results. An evaluation of a molecular model of II 
revealed a high probability for hydrogen bonding between the 3-beta-hydroxy hydrogen 
and the carbonyl oxygen of the 2-beta-methyl ester. This interaction would greatly 
decrease the reactivity of the hydroxy group to esterification and, when combined with 
the poor solubility of II, could explain the lack of success with these reaction attempts. 
Attempts to form amides at the 3-beta-position of .11 using the Ritter reaction were 
also futile. Even though this reaction is a standard for the synthesis of amide from 
alcohols, the intramolecular hydrogen bonding described for II could also contribute to 
the lack of reactivity in this reaction as well as in the esterification reaction. 
The N-demethylation of cocaine (I) or BE (III) using the KMN04 oxidation 
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method did not appear to be as facile as reported (57). However, modification of a 
procedure employing a-chloroethyl chloroformate to produce N-demethyl cocaine (V) 
proved efficient. The use of reductive alkylation to form N-alkyl derivatives of V 
produced satisfactory yields of compounds of analytical purity while avoiding the 
disadvantages of direct alkylation. Likewese, standard acylation procedures provided a 
series of N-acylated derivatives of V of satisfactory yields and purity. 
The synthetic procedures leading to the formation of potential prodrugs for both 
III and the respective NSAID employed proved to be satisfactory. The reduction of III 
to its corresponding 2-beta primary alcohol, BOH (IlIa), was straightforward and 
efficient. The esterification of this primary alcohol with either ibuprofen, naproxen or 
indomethacin was accomplished using the carbonyldiimidazole activated acyl carrier and 
led to limited yields of each product. However, enough purified material of each product 
was isolated to obtain NMR, GC/MS and IR structural confirmation. 
Biological Activity 
For the N-alkyl serIes of norcocaine (V) derivatives, only the N-butyl (Vd) 
demonstrated in vitro activity. While Vd was equipotent with I in blocking the uptake 
of PH] dopamine , it had a significantly lower affinity than I for transporter binding and 
was not found to be suitable candidate for in vivo evaluation. While the significance of 
the activity of V d is unclear from these results, it can be concluded that any increase in 
the size of the N-alkyl beyond the methyl group of I leads to a decrease in both 
transporter binding affinity and in [3H]dopamine uptake. These results are consistent 
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with an earlier study (65) in which the replacement of the N-metbyl group of cocaine 
with sterically larger groups reduced activity. 
None of the N-acyl derivatives of V demonstrated meaningful transporter binding 
affinity nor [3H]dopamine uptake activity. N-acylation of the secondary amine of V 
appears to irradicate meaningful transporter binding affinity and pH]dopamine uptake 
activity as well. The latter would be expected to be associated with the loss of basic 
character of the nitrogen and the related loss of an ionic attraction for the receptor. 
These results are consistent with those reported by Abraham for N-acetyl norcocaine(65). 
However, it is important to note that Kozikowski(48) has reported sulfonamide derivative 
of norcocaine that have similar and/or greater activity than cocaine in [3H]mazindole 
binding and in [3H]dopamine binding studies. From these results it can be concluded 
that, while the ionic attraction associated with the basic tertiary nitrogen of cocaine may 
contribute to its binding and subsequent activity, compounds containing a neutral nitrogen 
bridge can also possess a high binding affinity, which indicates that a basic nitrogen is 
not essential for this activity. 
FUTURE RESEARCH 
Priorities for future research include the following: 
1. Testing the benzoylecgonine/NSAID derivatives in arthritic animal models. 
2. Testing the N-alkyl and N-acyl benzoylecgonine derivatives in arthritic models and 
as cocaine antagonists. 
3. Synthesizing additional benzoylecgonine/NSAID ester to include the more potent 
NSAIDs. 
4. Continued efforts to synthesize 3-beta-analogs of benzoy lecogonine to include its 
3-beta-amide isoester. 
5. Elucidation of the effects of various modifications of the cocaine nucleus on the 
cloned dopamine transporter. 
REFERENCES 
1) Eds. Rodman, G.P., C. McEwen, and S.L. Wallace, Primer on the Rheumatic 
Diseases. (7th ed.), National Arthritis Foundation, Atlanta, GA (1973). 
2) Smith,C.A. and F.C. Arnett. "Epidemiologic Aspects of Rheumatoid Arthritis". 
Clinical Orthopaedics and Related Research. 265, pp 23-35, 1991. 
3) Wilson and Giswold's Textbook of Organic and Medicinal Chemistry, ed. J.N. 
Delgado and W.A. Remers (9th ed), J.B. Lippincott Co., Philadelphia, PA 
(1991). 
4) Saunders, P.A. and D.M. Grennan, "Nonsteroidal Antiinflammatory Drugs vs. 
Simple Analgesics in the Treatment of Arthritis tI. Baillieres' Clinical 
Rheumatology, 4,2, pp 371-85, 1991. 
5) Faye, W.O. Principles of Medicinal Chemistry,(3rd ed) Lea and Febiger, 
Philadephia, P A (1989). 
6) Weinblatt, M.E. and A.L. Maier, "Disease Modifying Agents and Experimental 
Treatments in Rheumatoid Arthritis. " Clinical Orthopaedics and Related Research, 
265, pp 103-105, April 15, 1991. 
7) Chang, Y., "Immunosuppressive and Immunostimulatory Agents in Rheumatoid 
Arthritis". Annual Reports In Medicinal Chemistry, 11, pp 138-48, 1976. 
8) Sommers, L. "Esterene in the Treatment of Rheumatoid Arthritis" , Arthritis News 
Today, 2:(No. 7) April 1980. 
9) Somers,L.A., R. Bingham, V. S. Myers, C. Thorsen, "Cocaine, Treatment of 
Rheumatoid Arthritis: a Neuromuscular Dysfunction u • Presented at the First 
Annual Conference on Arthritis, Tel Aviv, Israel, November, 1981. 
10) Muhtadi, F.J., A. A. AI-Badr, "Cocaine Hydrochloride:, Analytical Profiles of 
Drug Substances, K. Florey, ed., 15; pg 177, Harcourt-Brace, Jovanovich, FL 
1986. 
95 
11) Cregler,L. L., H. Mark, "Special Report: Medical Complications of Cocaine 
Abuse". N. England J. Med. 315, No. 23, 1495-1500, 1986. 
12) "Cocaine and Its Major Metabolite, Benzoylecgonine," NIDA Res ear c h 
Monogr., Chapter 7, 90-109, 1980. 
13) Hawks, R.L., I.J. Kopin, R. W. Colburn, N. B. Thoa, "Norcocaine: A 
Pharmacologically Active Metabolite of Cocaine Found in Brain." Life Sciences 
15: 2189-2195, 1974. 
14) Matsubara, K., M. Kagawa, and Y. Fukui. " In Vivo and In Vitro Studies on 
Cocaine Metabolism: Ecgonine Methyl Ester As A Major Metabolite of Cocaine" . 
Forensic Science International. 26: 169-180, 1984 
15) Jindal, S.P., T. Lutz and P. Vestergaard. "Mass Spectrometric Determination of 
Cocaine and its Biologically Active Metabolite, Norcocaine, in Ruman Urine". 
Biomedical Mass Spectrometry. 5: 658-662, 1978. 
16) Gawin, F.R.and E.R. Ellinwood, Jr. "Cocaine Dependence". Ann. Rev. Med., 
40: 149-161, 1989. 
17) Misra, A. L., P.D. Nayak, R. Block, S. J. Mule, "Estimation and Disposition 
of 3[H]benzoylecgonine and Pharmacological Activity of Some Cocaine 
Metabolites". Communications J. Pharm. Pharmac, 27:784-789, 1975. 
18) Bagchi, S.P. and M.A. Reilly, "Intraneuronal Dopaminergic Action of Cocaine 
and Some of Its Metabolites and Analogs". Neuropharmacology, 22: No. 11, 
1289-1295, 1983. 
19) Misra, A.L. and S.J. Mule. "Calcium-Binding Property of Cocaine And Some of 
Its Active Metabolites--Formation of Molecular Complexes". Research 
Communications in Chemical Pathology and Pharmacology. 11: No.4, 663-
666, 1975. 
20) Reith, M.E.A., B.E. Meisler, H. Sershen, A. Lajtha, "Structural Requirements 
for Cocaine Congeners to Interact with Dopamine and Serotonin Uptake Sites in 
Mouse Brain and to Induce Stereotyped Behavior". Biochemical Pharmacology, 
35:7, 1123-1129, 1986. 
21) Daum, S.J., C.M. Martini, R. K. Kullnig, R. L. Clarke, "Compounds Affecting 
the Central Nervous System. I. Tropane-2B,3B-diol Derivatives. A Reverse Ester 
of Cocaine". J. Org. Chern., 37:10,1665-1669,1972. 
22) Johanson, C. E. , M. W. Fischman, "The Pharmacology of Cocaine Related to 
96 
its Abuse" Pharmacol. Rev. 41(1), 3-53, 1989. 
23) Griffiths, R. R., "Similarities in Animal and Human Drug-taking Behavior." In 
Advances in Substances Abuse. Mello, N. K., ed., JAI Press, Inc., Greewich, 
CT, 1: pp 1-90, 1980. 
24) Carroll, F. I., A. H. Lewin, P. Abraham, K. Parham, J. W. Boja, M. J. Kuhar, 
"Cocaine Receptor: Biochemical Characterization and Structure-Activity 
Relationships of Cocaine Analogues at the Dopamine Transporter". J. Med. 
Chern. 35:6,969-981, 1992. 
25) Kuhar, M. J., M. C. Ritz, R. J. Lamb, R. Goldberg, "The Dopamine Hypothesis 
of the Reinforcing Properties of Cocaine". TINS. 14(7): 299-302, 1991. 
26) Ritz, M. C., R. J. Lamb, S. R. Goldberg, M. J. Kuhar, "Cocaine Receptors on 
Dopamine Transporters are Related to Self-administration of Cocaine" Science, 
237: 1219-1223, 1987. 
27) Bergman, J. S., K. M. Johnson, A. P. Kozikowski, "Effects of Kappa Alkaloids 
on Schedule-controlled Behavior of Squirrel Monkeys" J. Pharmacol. Exp. Ther. 
25: 150-155, 1989. 
28) Ettenburg, A., H. O. Pettit, F. E. Bloom, G. F. Koob, "Heroin and Cocaine 
Intravenous Self-administration in Rate: Mediation by Separate Neural System" 
Physchopharmacology 78: 204-209,1982. 
29) De La Garza, R., C. E. Johanson, "Effects of Haloperidol and Physostigmine 
on Self-administration of Local Anesthetics" Pharmacol, Bioche. Behav. 17: 1295-
1299, 1982. 
30) Woolverton, W. L., L. I. Goldberg, J. Z. Ginos, "Intravenous Self-
administration of Dopamine Receptor Agonists by Rhesus Monkeys" J. Pharmacol 
Exp. Ther. 230: 678-683, 1984. 
31) Sellers, E., M., "Pharmacokinetic and Phamacodynamic Drug Interactions: 
Implications for Abuse Liability Testing". NIDA Res. Monogr. Ser. 92: 287-
306,1989. 
32) Reith, M. E. A., G. Selmeci, "Radiolabelling of Dopamine Uptake Sites in Mouse 
Striatum: Comparison of Binding Sites for Cocaine, Mazindol, and GBR 12935." 
Naunyn-Schmiedeberg's Arch. Pharmacol., 345, 309-318, 1992. 
33) Gawin, F. H., "Cocaine Addiction: Psychology and Neurophysiology." Trends 
Pharmacal. Sci., 13, 193-200, 1992. 
97 
34) Gawin, F. H., E. H. Ellinwood, "Cocaine and Other Stimulants: Actions, Abuse, 
and Treatment." New Engl. J. Med., 318, 1173-82, 1988. 
35) Khantzian, E. J., N. J. Khantzian, "Methylphenidate Treatment of Cocaine 
Dependence--A Preliminary Report." J. Substance Abuse. 1: 107-112, 1984. 
36) Andersen, P. H. "The Dopamine Uptake Inhibitor GBR 12909: Selectivity and 
Molecular Mechanism of Action." Eur. J. Pharmacal. 166:493-504, 1989. 
37) Krueger, B. K., " Kinetics and Block of Dopamine Uptake in Synaptosomes 
from Rat Caudate Nucleus". J. Neurochem. 55:260-267, 1990. 
38) Kuhar, M. J." Neurotransmitter Uptake: A Tool in Identifying Neurotransmitter-
specific Pathways". Life Sci. 13: 1623-1634, 1973. 
39) Reith, M. E. A., H.Sershen, A. Lajtha, "Saturable [3H] Cocaine Binding in the 
CNS of the Mouse" . Life Sci. 27: 1055-1062, 1980. 
40) Kennedy, L. T., I. Hanbauer, "Sodium-sensitive Cocaine Binding to Rat Striatal 
Membrane: Possible Relationship to Dopamine Uptke Sites". J. Neurochem. 41: 
172-178, 1983. 
41) Madras, K. "Effects of Cocaine Binding Sites In Caudate-Putamen". L 
Pharmacol.Exp. Ther. 251: 131-141, 1989. 
42) Calligaro, D. 0., M. E. Eldefrawi, "High Affinity Stereospecific Binding of 
[3H] Cocaine in Striatum and its Relationship to the Dopamine Transporter." 
Membrane Biochern. 7: 87-106, 1988. 
43) Cook, C. E., "Pharmacokinetic Studies of Cocaine and Phencyclidine in 
Man." In Pharmacokinetics and Pharmacodynamics of Psychoacitive Drugs; 
Bamett,g., Chiang, C. N., eds., Biochemical Publication, Foster City, CA, 1985, 
pp 48-74. 
44) Kozikowski, A. P., L. Xiang, J. Tanaka, J. S. Bergmann, K. Johnson, "Use of 
Nitrile Oxide Addition (NOC) Chemistry in the Synthesis of Cocaine Analogues: 
Mazindol Binding and Dopamine Uptake Studies." Med. Chern. Res. 1: 312-321, 
1991. 
45) Kozikowski, A. P., M. Roberti, L. Xiang, J. S. Bergmann, P. M. Callahan, K. 
A. Cunningham, K. M. Johnson, "Structure-activity Relationship Studies of 
Cocaine: Replacement of the C-2 Ester Group by Vinyl Argues Against 
Hydrogen Bonding and Provides an Esterase-resistant, High-affinity Cocaine 
Analogue." J. Med. Chern. 35: 4764-4766, 1992. 
98 
46) Kozikowski, A. P., M. Roberti, K. M. Johnson, J. S. Bergmann, R. G. Ball, 
"SAR of Cocaine: Further Exploration of Stuctural Variations at the C-2 Center 
Provides Compounds of Subnanomolar Binding Potency." Bioorg. and Med. 
Chern. Lett. 3(6): 1327-1332, 1993. 
47) Stang, P. J., M. Hanack, L. R. Subramanian, "Perfluoroalkanesulfonic Esters: 
Methods of Preparation and Application in Organic Chemistry. II Synthesis, 
85: 126, 1982. 
48) Kozikowski, A. P., M. K. Eddine Saiah, J. S. Bergmann, K. M. Johnson, 
"Structure-activity Relationship Studies of N-Sulfonyl Analogs of Cocaine: Role 
of Ionic Interaction In Cocaine Binding." J. Med. Chern. 37: 3440-3442, 1994. 
49) Stoelwinder, J., M. Roberti, A. P. Kozikowski, K. M. Johnson, J. S. Bergmann, 
"Differential Binding and Dopamine Uptake Activity of Cocaine Analogues 
Modified at Nitrogen." Biomed. Chern. Lett. 4: 303-308, 1994. 
50) Andrews, P. R., D. J. Craik, J. L. Martin, "Functional Group Contributions to 
Drug-Receptor Interactions." J. Med. Chern. 27:1648-1657, 1984. 
51) Kitayama, S., S. Shimada, J. Xu, L. Markham, D. M. Donovan, G. R. Uhl, 
"Dopamine Transporter Site-directed Mutations Differentially Alter Substrate 
Transport and Cocaine Binding" Proc. Nat!. Acad. Sci. U.S.A. 89: 7782-7785, 
1992. 
52) Vogel's Textbook of Practical Organic Chemistry. 5th ed., B. S. Furniss, A. J. 
Hannaford, P. W. G. Smith, and A. R. Tatchell, eds., Longman Scientific and 
Technical Publishers, 1991, P 698. 
53) Paul, R., G. W. Anderson, "N,N'-Carbonyl Diimidazole, A New Peptide 
Forming Agent." J. Am. Chern. Soc., 82,4596-4600, 1960. 
54) Paul R., and G.W. Anderson, "N,N'-Carbonyldiirnidazole in Peptide Synthesis. 
III. A Synthesis of Isoleucine-5-Angiotensin II Amide-I." J. of Organic 
Chemistry, 27: 2094-2099, 1962. 
55) Saha, P. Schultz, J. Rapoport, "1,1' -Carbonylbis-(3-Methylimidazolium) triflate: 
An Efficient Reagent for Amino Acylations:" J. Am. Chern. Soc. 111: 4856-
4859, 1989. 
56) Bell, M.R., A. Archer, "L (+)-2-Tropinone", Journal of the American 
Chemical Society, 82: 4642-44, 1960. 
57) Findley, S. P. "The Three-Dimensional Structure of the Cocaines. Part I. 
99 
Cocaine and Pseudococaine." J. Am. Chern. Soc. 76:11, 2855-2862, June, 
1954. 
58) Stenberg, V. J., N. K. Narain, S. P. Singh, S. S. Parmar, "An Improved 
Synthesis of Norcocaine." J. Heterocyclic Chern. 13:363-364, 1976. 
59) Fodor, G., K. Nador, "The Stereochemistry of the Tropane Alkaloids. Part 
1. The Configuration of Tropine and ~-Tropine." J. Chern. Soc., 721: 721-727, 
1953. 
60) Baldwin, S.W., P.W. Jeffs, S. Natarajan, "Preparation of Norcocaine. "Synthetic 
Communications, 7(1): 79-84, 1977. 
61) Borne, R.F., J.A. Bedford, J. L. Buelke, C. B. Craig, T. C. Hardin, A. H. 
Kibbe, M. C. Wilson, ttBiological Effects of Cocaine Derivatives I: Improved 
Synthesis and Pharmacological Evaluation of Norcocaine. " J. Pharm. Sci. 66 (1): 
119-120, 1977. 
62) Meltzer, P.C., A. Y. Liang, A. L. Brownell, D. R. Elmaheh, B. K. Madras, 
"Substituted 3-Phenyl Tropane Analogs of Cocaine: Synthesis, Inhibition of 
Binding at Cocaine Recognition Sites and Positron Tomography Imaging." L. 
Med. Chern. 36: 855-862, 1993. 
63) Lazer, E.S., N. D. Naranjan, D. Aggarwal, G. J. Hite, K A. Nieforth, R. T. 
Kelleher, R. D. Spealman, C. R. Schuster, W. Wolverton, "Synthesis and 
Biological Activity of Cocaine Analogs I: N-alkylated Norcocaine Derivatives." 
J. Pharm. Sci. 67: 12, 1656-1658, 1978. 
64) Milius, R.A., J. K. Saha, B. K. Madras, J. L. Neumeyer, "Synthesis and 
Receptor Binding on N-substituted Tropane Derivatives. High-affinity Ligands for 
the Cocaine Receptor." J. Med. Chem.34:1728-1731, 1991. 
65) Abraham, P., J. B. Pitner, A. H. Lewin, J. W. Boja, M. J. Kuhar, F. 1. Carroll, 
"N -modified Analogues of Cocaine: Synthesis and Inhibition of Binding to the 
Cocaine Receptor." J. Med. Chern. 35: 141-144, 1992. 
(67) Vogel's Textbook of Practical Organic Chemistry, 5th ed., B. S. Furniss, A. J. 
Hannaford, P. W. G. Smith, and A. R. Tatchell, eds., Longman Scientific and 
Technical Publishers, 1991, pp 776-777. 
68) Lane, C.P. "Sodium Cyanoborohydride: A Highly Selective Reducing Agent," 
Synthesis, 135-146, March 1975. 
69) Borch, R.F., M.D. Bernstein, H. D. Durst, "The Cyanohydridoborate Anion as 
100 
a Selective Reducing Agent." Journal of The American Chemical Society, 93: 12, 
2897-2904, 1971. 
70) Oka, Y., M. Motohashe, " Synthesis of Conformationally Rigid Catecholamine 
Derivatives." Chern. Pharm. Bull. 25 (4):632-639, 1977. 
71) March, J. Advanced Organic Chemistry. 4th ed., John Wiley and Sons, New 
York, pp 427-428, 1992. 
72) Krimen, L.I., The Ritter Reaction." Organic Reactions, Ch. 3, pg 251, New 
York, 1969. 
73) Lewin, A.H., Y. Gao, P. Abraham, J. W. Baja, M. J. Kuhar, F. I. Carroll, "26-
Substituted Analogues of Cocaine. Synthesis and Inhibition of Binding to the 
Cocaine Receptor." J. Med. Chern. 35: 135-139, 1992. 
APPENDIX A 





EXP2 PULSf SfQUENCf. S2PUL 
DATE 09 -18 -94 19. 0/. '13 
SOLVENT DMSO 
~ILE I' .1 
ACQUISITION DEC . & VT \ 
TN 1.000 ON 1. 000 
SW 4500 .'5 DO '·450 .0 
AT 1.g98 OM NNN 
NP 17984 DMM C 
PW 6.0 OHP 20.0 
P1 0 nPLVL 54.0 
01 1.000 
02 0 PROCfSStNG 
TO 0 Sf 0.318 
NT 240 L.B 1.000 cr 240 ~ATH I 
TPWR ~2 . 0 
PW90 12.8 DISPLA''( 
FB 2~00 ')P '-172 . ,~ 
AS 0 wP 4500 .1 
SS 0 VS 1010 
IL N (" .)L () 
1N N we 1100 
OP Y I~ 100 
ALO CK N r~l ~l2 . ,~ 
~~P 0 
fh to 
TNS 1 . l~00 
"'--- , ... _ . ___ ~~f')~-- J---t-..J J ___ . '
'J I \ ~ #t --" -' ... 
\ " - ---' Jl ,- Jv ~ ilf/JJ.) L __ ,,-, '.J.. ___ _ 
I I II I I I I I I r I I I I I I I I I 
12 10 8 6 4 2 0 PPM 












01/12/95 19:34:00 + 11:47 
SAMPLE: IPC 
CONDS.: ? 















ATA: L~ "1179 































,,\ \ '~1\ .\ \\ \ 
of ".\\ \\//\\, \ 
. , ' " \ 11 , .. ' 




-, ") ', _. 










filename I cI\tmp 
scans ,16 
detector • DTGS 
" ""T 
isopropylnoreoeaine (Ve) 
' 1 ' _.. , ",.....: . '., ( " .. 
' . 1,..4 " ~ ~ c; . ~ :j _ . , ,LJ , I : ) 
~ 5 
2 ~~ OO 2000 1600 
lA' C': onumberG 
Tue Feb 07 14, 02, 31 1995 
-.- ---
8 
~ ')(""n BGO .. ~ '-J ... .J 
s1gno1 goln I 1 
resolution 4 
-.-- - - - ---
ExP3 .' PllS~ S2Pll. 
.1.,.~W.CDcl3 07: ~ 20 
.- FItEf~. ;; H 
• • ~ : I :' ~ ':: ,; :.~' I' •• 
. ·)ACauISITION 
TN ... ,'. : .. ;::. 1.000 
.. SW ' >~.-Y·4500.5 
': .'. AT- · .... 1.998 
: NP . I 17984 
.' PW .:· . 6.0 
') Pi·::-' ~ 0 
:. Of> 1.000 
". 02 ·0 
'·' TO 0 
NT 240 
·. CT 240 
. TPWR 52.0 
. PW90 12.8 



























I, 'I' i' . i 
: ~ ! I ' , : ~ 
I ~ , I I ! ;, r J , I ' I I I 
. . " 
I i I ' \ ~~\ 
Ly....J L.r..J L-r-" .JL., .. -' r--,_.J L .·.r _. ; l. . .._ . . . !L..- .: 















02/13/95 18:54:00 + 11:02 
SAMPLE: 8lCNC 
co~ms.: HORKUP 





341 357 372 
350 
un,,..,; L...O~ 'ft'J..L~~ 




405 417 433 450 
400 450 500 
Benzoylnorcocaine (Ve) 













Representative Analytical Spectra for the Benzoylecgonine Derivatives 
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Run started on 19 Jul,1995 at 08:34:11 
and consists of 811 scans acquired at a rate of 1.111 second s 
So 1 i d pl-obe 
BElB MW 463 
Masses were acquired as: 
50- 600 
Displag ~ axis froM 325 





to 69& on tQl'ked plot 
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Scan at 31.9333 
74Z8 
325 359 375 499 425 459 475 589 525 SSg S75 699 
2-(4-iSOQutylphenyl)propionic acid, (3-b~nzoyloxy-2-tropylmethyl ester 
